

CURRICULUM VITAE  
M. DONALD BLAUFOX, M.D., PH. D.  
101 Drake Smith Lane  
Rye, New York 10580  
(914) 967-7240 Revised 5/23/2016

PERSONAL

Birth Date: July 19, 1934, New York, N.Y.  
Marital Status: Married, Three Children

EDUCATION

Bronx High School of Science, Bronx, New York	1949-1952
Harvard College, Cambridge, Mass.	1952-1955
State University of New York, College of Medicine at New York City, Downstate Medical Center, Brooklyn, N.Y.	1955-1959
University of Minnesota, Mayo Foundation, Rochester, Minn.	1960-1964

POST-GRADUATE TRAINING

Jewish Hospital, Brooklyn, N.Y. (Internship)	1959-1960
Mayo Foundation for Medical Education and Research, Rochester, Minnesota (Internal Medicine)	1960-1964
Advanced Research Fellow, American Heart Association; Assistant in Medicine and in Radiology, Peter Bent Brinham Hospital; Research Fellow, Harvard Medical School	1964-1966

DEGREES

M.D. State University of New York, Downstate Medical Center	1959
PhD. In Medicine, University of Minnesota	1964

CERTIFICATION

American Board of Internal Medicine	1966
American Board of Nuclear Medicine	1972
Specialist in Clinical Hypertension (ASH)	1999

MEDICAL LICENSE

New York -- 096301

HONORS, AWARDS AND FELLOWSHIPS

Google Analytics H index 54	2018
Bicknell Lecturer, American Urologic Association	2016
Dean's Council, Harvard Medical School,	2014
Jessup Society, American Museum of Natural History	2006
1636 Society, Harvard College	2014
Southeastern Chapter-Society of Nuclear Medicine, The R. Edward Coleman, MD Lecture: Past, Present and Future of Renal Scintigraphy	2012
Fellow, American College of Nuclear Medicine	2010
M. Donald Blaufox Hall of Diagnostic Instruments	2009
Dean's Society, Case Western Reserve University	2009
M. Donald Blaufox Laboratory for Molecular Imaging	2006
Fellow, The American Society of Nephrology	2005
Lifetime Member The National Atomic Museum	2004
Advisory Board, Mobile Medical Museum	2002
Member, Int'l Advisory Committee of 34 <sup>th</sup> Annual Conf, Society Nuclear Medicine, India	2002
Lifetime Achievement Award, International Society of Radionuclides in Nephro-Urology	2001
Atis K. Freimanis Visiting Professor, Michigan State University	2001
Highly Commended, Basis of Medicine, Medical Book Competition, Awarded by British Medical Association for Blood Pressure Measurement: An Illustrated History	1999
Honorary Board Member, Eichold-Heustis Medical Museum of the South	1999
Keynote Address, British Nuclear Medicine Society, Brighton, UK	1998
Honorary Professor of Medicine, Shanxi Medical University Taiyuan, Peoples Republic of China	1997
Fellow, Royal Society of Medicine	1995

Fellow, The Society of Uroradiology	1995
The Ninth Annual Daniel R. Biello Memorial Lecture, Mallinckrodt Institute of Radiology	1995
The Second Annual Corporate Lecture, Medical History Society of New Jersey	1994
Fellow, Council on Cardiovascular Radiology of the American Heart Association	1992
George Taplin Memorial Lecturer, Western Regional Meeting of the Society of Nuclear Medicine	1991
Corresponding Member, Swiss Society of Nuclear Medicine	1990
Sarabhai Memorial Oration Award from the Society of Nuclear Medicine, Lucknow, India	1989
First Annual Berson-Yalow Award of the Greater New York Chapter of the Society of Nuclear Medicine	1989
Fellow, New York Academy of Medicine	1984
Fellow, American College of Nuclear Physicians	1982
Albert Lasker Special Public Health Service Award for the Hypertension Detection and Follow-Up Program, given to the NIH (M. Donald Blaufox, Principal Investigator, New York Center)	1980
Fellow, Council for High Blood Pressure Research American Heart Association	1980
Fellow, American College of Physicians	1977
Sigma Xi	1963
Mayo Foundation for Medical Education and Research Edward Noble Foundation Award	1963
Medical School:	
Joseph Collins Foundation Scholarship	1955-1959
Seymour Schatzberg Memorial Scholarship	1955-1959
Harvard College Scholarship	1952-1955
Edgar Cigelman Award	1952

#### ACADEMIC APPOINTMENTS

##### Present

<u>Albert Einstein College of Medicine</u>	
Professor and University Chairman Emeritus	2012-Present
Professor of Medicine, Emeritus	2012-Present
Professor of Radiology, Emeritus	2012-Present

##### Past

<u>Albert Einstein College of Medicine</u>	
Professor and University Chairman, Department of Nuclear Medicine	2000-2011
Professor and Chairman, Department of Nuclear Medicine	1982-2000
Professor of Medicine	1978-2012
Professor of Radiology	1976-2012
Associate Professor of Medicine	1972-1978
Associate Professor of Radiology (Nuclear Medicine)	1971-1976
Assistant Professor Medicine	1968-1972
Assistant Professor of Radiology (Nuclear Medicine)	1966-1971
Associate in Medicine	1967-1968
Instructor in Medicine	1966-1967

#### PROFESSIONAL APPOINTMENTS

##### Present

University Chairman Emeritus, Department of Nuclear Medicine	2012-Present
--	--------------

##### Past

<u>University Chairman, Department of Nuclear Medicine</u> Montefiore Medical Center	2000-2011
<u>Chairman, Department of Nuclear Medicine</u> Albert Einstein College of Medicine Montefiore Medical Center Bronx Municipal Hospital Center North Central Bronx Hospital	1982-2000
<u>Director, Divisions of Nuclear Medicine</u> Albert Einstein College of Medicine Montefiore Hospital and Medical Center Bronx Municipal Hospital Center	1976-1982

<u>Director, Division of Nuclear Medicine</u>	1966-1976
Albert Einstein College of Medicine	
Weiler Hospital of the Albert Einstein College of Medicine	
Bronx Municipal Hospital Center	
Co-Director, Division of Hypertension,	1974-1976
Albert Einstein College of Medicine	

HOSPITAL APPOINTMENTS

Attending Physician, Weiler Hospital of the Albert Einstein College of Medicine	1966-2012
Attending Physician, Montefiore Medical Center	1976-2012
Attending Physician, Bronx Municipal Hospital Center	1966-2006
Attending Physician, North Central Bronx Hospital	1976-2006

OTHER PROFESSIONAL ACTIVITIES(Present)

Reviewer, American Journal of Radiology	2006-Present
Technical Expert, International Atomic Energy Agency	1995-Present
Member, Advisory Committee, Section on Nuclear Medicine	1993-Present
New York Academy of Medicine	
Member, Scientific Committee, Radionuclides in Nephrourology	1972-Present

Past

Member, ASH Committee on Hypertension Specialists	1997-2015
Consultant, Healthcare Systems Engineering Program, Lehigh University	2012-2013
World Congress of Nuclear Medicine and Biology	
Member, Academy of Molecular Imaging	1995-2013
Reviewer, Shota Rustaveli National Science Foundation	2011-2012
Republic of Georgia	
Member, Diagnostic Radiology Safety Group-FOJP	2010-2012
Member, Genitourinary Track, Scientific Committee for the 9th	2005-2012
Adjunct Professor, Physics & Technology, Bronx Community College	1988-2012
Member, Library Committee, New York Academy of Medicine	1985-2009
President, Medical Collectors Association	1984-2003
Reviewer, American Medical Association's Diagnostic and	
Therapeutic Technology Assessment Program	1982-1998
Member, BLIP Users' Advisory Committee, Brookhaven	
National Laboratory	1992-1996
Reserve Reviewer, Clinical Trials Review Committee,	
National Heart, Lung & Blood Institute	1992-1996
Chairman, Section on Nuclear Medicine	1993-1995
New York Academy of Medicine	
Member, American Association for the History of Medicine,	1994
Local Arrangements Committee	
Member, International Liaison Committee World Federation	
Nuclear Medicine and Biology	1992-1994
Member, Committee on Position Statement on the Role of	
Radionuclide Scintigraphy in the Evaluation of	
Patients with Hypertension, American College of Cardiology	1992-1993
Member, Subcommittee on Non-Pharmacologic Therapy of the	
Joint National Committee on Detection, Evaluation and	
Treatment of High Blood Pressure V	1991-1992
Member, Clinical Trials Review Committee, National Heart, Lung & Blood Institute	1988-1992
Member, Membership Committee, The American Society of Hypertension	1986-1991
Chairman, Ad Hoc Committee on the Historical Collection,	
New York Academy of Medicine	1991
American Board of Nuclear Medicine, Chairman	1990

Member, Board of Directors	1984-1990
Member, National Institutes of Health Working Group on Detection and Treatment of Renovascular Disease	1984
Member, Advisory Committee for Hypertension in the Elderly, City of New York Department of Health	1983-1989
Co-Chairman, Scientific Committee Radionuclides in Nephrourology	1983-1986
Member, Working Group on the Definition of Normal and High Blood Pressure of the National Heart, Lung and Blood Institute	1981-1985
Member, Hypertension Advisory Committee, New York City Department of Health	1975-1976
Member, Administrative Council for Nuclear Medicine of the Veterans Administration	1972-1973
Member, Panel on Radiopharmaceuticals for the Committee on Scope of the United States Pharmacopeia	1970-1976
Member, Program Committee, New York Society of Nephrology	1969-1971
Member, Nominating Committee, New York Society of Nephrology	1968-1969
Consultant, Kidney Disease Control Section, Chronic Disease Control Program, United States Public Health Service	1967-1972
Member, Standards Committee, Association for the Advancement of Medical Instrumentation	1967-1969

#### The Society of Nuclear Medicine (National)

##### Past and Present

Representative, ACR Clinical Criteria, Appropriateness Committee	2012-2016
Chairman, Renal Scintigraphy Guidelines	2012-2018
Co-Chairman, PET Committee, NY Chapter	2001-2005
Member, Guidelines and Communications Committee Renovascular Hypertension Guideline Task Force	1998-2010
External Guidelines Task Force	1997-2010
Chairman, History of Medicine Advisory Committee, New York Academy of Medicine	1995-2004
Member, Committee on Commercial Affairs	1993-1995
Member, Special Committee of Business Advisors	1990-1993
Member, Socio-Economic Committee	1989-1996
Advisory Committee on Radiopharmaceuticals	1987-1988
Member, Board of Trustees	1983-1987
Member, Executive Committee	1979-1982
Chairman, Publications Committee	1979-1982
Member, Finance Committee	1979-1982
Member, Committee on Recertification of Physicians	1977-1980
Member, Committee on Course Accreditation and Continuing Education	1977-1979
<sup>99m</sup> Tc DTPA (Sn) Task Group Member, MIRD Committee on Radiation Dosimetry	1977-1979
Member, Board of Trustees	1976-1980
Member, Committee on Continuing Education	1970-1976
	1972-1980

##### Scientific Program Committee

Vice Chairman - 1972
Subchairman, Renal Section - 1982
Subchairman, Renal Section - 1988
Reviewer, 1973-1981, 1983-1987, 1989-1998, 1999-Present

#### The Society of Nuclear Medicine, Greater New York Chapter

##### Past and Present

Chairman, Nominating Committee	1976
President	1975-1976
Chairman, Committee on Education and Training	1975-1976
Member, Nominating Committee	1972-1974
Member, Nominating Committee	1993

## EDITORIAL POSITIONS

Medical Museum, <u>Dot Med Business News</u> , Monthly Feature	2011-Present
<b><u>Journals and Periodicals</u></b>	
Scientific Advisory Board, <u>Turkish Journal of Nuclear Medicine and Molecular Imaging</u>	2015-Present
Editorial Board, <u>The Scientific World Journal: Molecular Imaging Domain</u>	2011-Present
Editorial Board, <u>The Open Nuclear Medicine Journal</u> ( <a href="http://www.benthamscience.com/open/tonmedj/">http://www.benthamscience.com/open/tonmedj/</a> )	2008-2011
Editor-in-Chief, <u>Current Medical Imaging Reviews</u>	2005-2006
Editorial Board, <u>Current Hypertension Reviews</u> ( <a href="http://www.benthamscience.com/chr/">http://www.benthamscience.com/chr/</a> )	2004-2011
Editorial Board, <u>Current Medical Imaging Reviews</u> ( <a href="http://www.benthamscience.com/cmjr/">http://www.benthamscience.com/cmjr/</a> )	2004-2005
Editor, <u>Endocrine, Renal and Vascular Sections, Yearbook of Nuclear Medicine</u>	1994-2007
Editorial Board, <u>American Journal of Hypertension</u>	1987-2014
Editorial Board, <u>Cardiology World News</u>	1984-2000
Editorial Board, <u>The Quarterly Journal of Nuclear Medicine</u> (Formerly <u>Journal of Nuclear Medicine and Allied Sciences</u> )	1982-Present
Reviewer, <u>American Journal of Roentgenology</u>	1977-Present
Co-Editor, <u>Seminars in Nuclear Medicine</u> , W.B. Saunders Company, Philadelphia, PA	1970-Present
Advisory Editor, <u>Communications in Nuclear Medicine</u>	1979-2004
Editorial Board, <u>Nephron</u> , S. Karger, Basel, Switzerland	1977-2004
Section Editor for Diagnostics and Techniques, <u>Current Opinions in Nephrology and Hypertension</u>	1992-1996
Editorial Board, <u>Uroradiology</u> , Springer-Verlag, Berlin, Germany	
Editorial Board, <u>Renal Failure</u>	1985-1989
Co-Editor, <u>Albert Einstein Teaching Series in Nuclear Medicine</u> , Med-Com, New York, N.Y.	1977-1984
Editorial Board, <u>Journal of Nuclear Medicine</u>	1973-1981
Consultant, <u>PDR for Nuclear Medicine and Radiology</u> Medical Economics, Oradell, New Jersey	1971-1980

## SOCIETIES

American Association for the History of Medicine  
American College of Nuclear Physicians (Fellow)  
American College of Physicians (Fellow)  
American Heart Association  
    Council on Cardiovascular Radiology (Fellow)  
    Council on High Blood Pressure Research (Fellow)  
    Council on Kidney in Cardiovascular Disease  
American Medical Association  
American Nephrology Society  
American Society of Hypertension  
European Association of Museums of the History of Medical Sciences  
European Society for Hypertension  
European Society of Nuclear Medicine  
International Scientific Committee for Radionuclides in Nephrourology  
New York Academy of Medicine  
New York Heart Association  
New York State Medical Society  
Royal Society of Medicine (Fellow)  
Society of Nuclear Medicine  
Westchester County Medical Society

## SOCIETIES (Past membership)(Date resigned)

European Society of Uroradiology (2012)  
International Society for Hypertension (2012)

Medical Collectors Association (2012)  
 Sigma Xi – (2012)  
 Uroradiology Society (Fellow) (1999)  
 American Physiology Society - (1997)  
 American Federation for Clinical Research - (1996)  
 International Society of Nephrology - (1996)

MEDICAL HISTORICAL EXHIBITIONS

The Dawn of Modern Medicine Bruce Museum, Greenwich Ct	2018-2019
National Museum of Civil War Medicine Frederick, Maryland	October, 2001
The National Museum of Nuclear Science & History Albuquerque, New Mexico	December, 2003
Dittrick Museum of Medical History Cleveland, Ohio	December, 2008

MAJOR RESEARCH FUNDED PROJECTS AND SOURCE OF SUPPORT

Principal Investigator

African American Study of Kidney Disease and Hypertension, National Institutes of Health	1994-1996
Nuclear Medicine Procedures in Hypertension, National Heart, Lung and Blood Institute	1988-1992
SCOR-NIH (Specialized Center of Research in Hypertension) 5P50HL 18323-18. (Project Co-Investigator)	1991-1993
Effect of Dietary Modification on Blood Pressure Control, National Heart, Lung and Blood Institute	1984-1991
Systolic Hypertension in the Elderly Program, National Heart, Lung and Blood Institute	1984-1991
Dietary Intervention Study for Hypertension, National Heart, Lung and Blood Institute	1980-1984
Surveillance of Mortality and Blood Pressure Control Status for Two Years in the Hypertension Detection and Follow-Up Program. National Heart, Lung and Blood Institute	1979-1981
New York Center, Hypertension Detection and Follow-Up Program, National Heart, Lung and Blood Institute	1972-1979
Improved Radiopharmaceuticals for Renal Studies, National Institutes of Health	1974-1977
Radiopharmaceuticals for Renal Evaluation, Picker Foundation	1972-1973
The Study of Reflux in Children with Radioisotopes, Public Health Service	1968-1970
Renal Blood Flow and Renin Secretion in Hypertension, National Heart and Lung Institute	1967-1970

Grants for the study of physiologic mechanisms of action of new antihypertensive drugs and radio-pharmaceuticals have been received between 1967 and present from Ciba Pharmaceuticals, Boehringer Ingleheim Ltd., E.R. Squibb &

Sons, Inc., Immunomedics, Inc., Lederle Laboratories, Mallinckrodt Medical Inc., Merck Frosst Laboratories, Inc., Pfizer, Inc., and Bristol-Myers Squibb.



## MEDICAL SCHOOL AND HOSPITAL COMMITTEES

<u>COMMITTEE</u>	<u>TITLE</u>	<u>DATES</u>
<u>Albert Einstein College of Medicine</u>		
Senate Council	Member	1984-2012
Chairmen's Committee	Member	1983-2012
Committee of Professors	Member	1982-2012
Various ad hoc Committees for Individual Promotions	Member and Chairman	1980-2012
Faculty Senate	Member	1973-2012
Radioisotope Committee	Chairman	1970-2012
Division of Clinical Programs, Working Party	Member	1996
Dean's Committee-Academic Policy & Planning Committee	Member	1985-1989
Dean's Task Force on Magnetic Resonance Imaging	Member	1985-1986
Technology Committee	Chairman	1984-1988
Promotions Committee (Professors)	Member	1984
Dean's Information Management and Library Committee	Member	1983-1987
Scientific Services	Chairman	1979-1989
Advisory Committee for the Computer Center	Member	1976-1977
Subcommittee on Affiliations	Member	1972-1973
Dean's Advisory Committee on Clinical Long Range Planning	Member	1971-1981
Computer Section of the Committee for Radioisotope Committee	Member	1966-1969
<u>Albert Einstein College of Medicine/Montefiore Medical Center</u>		
Unification Committee	Member	1985-1987
<u>SEARCH COMMITTEES</u>		
Chairman of the Department of Oncology	Member	1993
Chairman of the Unified Department of Pathology	Member	1992
Chairman of the Unified Department of Radiation Oncology	Member	1991-1992
Chairman of the Unified Department of Radiology	Member	1989-1991
Chairman of the Unified Department of Medicine	Member	1989-1990
Chairman of the Department of Urology	Member	1987
Chairman of the Unified Department of Radiology	Chairman	1985-1986
Chairman of the Unified Dept of Radiation Therapy	Chairman	1981-1983
<u>Montefiore Medical Center</u>		
Radioisotope Committee	Member	1983-Present
Medical Executive Committee of the Medical Staff	Member	1994-1995
Medical Executive Committee of the Medical Staff	Member	1991-1992
Committee for definition of a Policy of Ethics in Medicine	Member	1989
Ad Hoc Scientific Misconduct Committee	Member	1988-1989
Medical Executive Committee of the Medical Staff Medical Advisory Committee (Bed Replacement Program - MMC)	Member	1986
Task Force for Technological Services	Chairman	1985-1986
Research Policy Advisory Committee	Member	1985-1986
Task Force on Laboratories (Regionalization)	Member	1979-1980
<u>Bronx Municipal Hospital Center</u>		
Committee on Radium, Radiation and Radioisotopes	Member	1976-1997

## **Books**

Renal Section Editor, Nuclear Medicine, Krause BJ, Czernin J, Drzezga A, Schwaiger M (Eds), Springer-Verlag, Germany, 2014

Advisory Editor, Nuclear Medicine in Clinical Diagnosis and Treatment, Ell PJ, Gambhir SS (Eds), Churchill Livingstone, London, United Kingdom, 2004 (third edition).

Blafox MD, Past, Current and Future Developments of Nuclear Medicine Techniques: The Kidneys and Hypertension, Guest Editor, Q J Nucl Med. 46:245-248, 2002.

Blafox MD, An Ear to the Chest: The Evolution of the Stethoscope, Parthenon Publishing, London, United Kingdom, 2001

Naqvi NH, Blafox MD, Blood Pressure Measurement: An Illustrated History, Parthenon Publishing, London, United Kingdom, 1998.

Advisory Editor, Nuclear Medicine in Clinical Diagnosis and Treatment, Murray IPC and Ell PJ (Eds), Churchill Livingstone, London, United Kingdom, 1994 (first edition); 1998 (second edition)

Co-Editor, Radionuclides in Nephro-Urology, Proceedings of the Seventh International Congress, Blafox MD, Hollenberg NK and Raynaud C (Eds), S. Karger, Basel, Switzerland, 1990.

Editor, Evaluation of Renal Function and Disease with Radionuclides: The Upper Urinary Tract, Blafox MD, S. Karger, Basel, Switzerland, 1989, (second edition).

Co-editor, Radionuclides in Nephrourology, Proceedings of the Sixth International Congress, Delaloye A and Blafox MD (Eds), S. Karger, Basel Switzerland, 1987.

Co-Editor, Non Pharmacologic Therapy of Hypertension, Blafox MD and Langford H (Eds), S. Karger, Basel, Switzerland, 1987.

Chairman, Editorial Board (On behalf of the Hypertension Detection and Follow-Up Program), and Guest Editor, Results and Implications of the Hypertension Detection and Follow-Up Program, Progress in Cardiovascular Disease, Vol 29 (3)(S1), Nov/Dec. (Sonnenblick EH and Lesch M (Eds), Grune and Stratton, Orlando, Florida, 1986.

Co-Editor, Special Issue of Uremia Investigation, on the Proceedings of the Fourth International Symposium of Nephrology, Montecatini, Italy, 1985, on Newer Diagnostic Methods in Nephrology and Urology, Blafox MD and Bianchi C (Eds), Vol. 9(2), Marcel Dekker, Inc., New York, N.Y., 1986.

Co-Editor, Secondary Hypertension: Current Diagnosis and Management, Blafox MD and Bianchi C (Eds), Grune and Stratton, New York, N.Y., 1981.

Associate Editor, Radionuclides in Nephrology, Proceedings of the IV International Symposium, Boston, 1980, Hollenberg NK, Lange S (Eds), Georg Thieme Verlag, Stuttgart and New York, 1980.

Co-Editor, Unilateral Renal Function Studies, Proceedings of the International Congress (Bianchi C and Blafox MD, Eds), S. Karger, Switzerland, 1978.

Co-Editor, Radionuclides in Nephrology, Proceedings of the International Congress (zumWinkel K, Blafox MD and Funck-Brentano JL (Eds), Georg Thieme Verlag, Stuttgart, Germany, 1975.

Co-Editor, Radionuclides in Nephrology, Proceedings of the International Congress, Blafox MD, Funck-Brentano JL (Eds), Grune and Stratton, New York, N.Y., 1972.

Associate Editor, Pediatrics, Barnett H (Ed), 15th Edition, Appleton Century Crofts, New York, N.Y., 1972.

Editor, Evaluation of Renal Function and Disease with Radionuclides, Blaurock MD, S. Karger, Basel, Switzerland, 1972 (first edition).

**WEBSITE (e-book) -**

Curator, Museum of Historical Medical Artifacts, ([www.MOHMA.org](http://www.MOHMA.org)) , Blaurock, MD, Bronx, NY, 2009.

## **PEER REVIEWED ARTICLES**

1. Blafox M, Orvis A, Owen CA, Jr.: Compartment Analysis of the Radiorenogram and Distribution of Hippuran <sup>131</sup>I in the Dog. *Am. J. Physio.* 204:1059-1064, 1963.
2. Blafox M, Campbell J, Utz D, Owen CA, Jr.: Effects of Partial Nephrectomy on the Blood Pressure and Renal Function of Hypertensive Dogs. *J. Surg. Res.* 3:281-288, 1963.
3. Blafox M, Sanderson D, Tauxe W, Wakim K, Orvis A, Owen CA, Jr.: Plasmatic Diatrizoate <sup>131</sup>I Disappearance and Glomerular Filtration in the Dog. *Am. J. Physio.* 204:536-540, 1963.
4. Blafox M, Frohmuller H, Campbell J, Utz D, Orvis A, Owen CA, Jr.: Simplified Method of Estimating Renal Function with Iodohippurate <sup>131</sup>I. *J. Surg. Res.* 3:122-125, 1963.
5. Blafox M, Campbell J, Utz D, Owen CA, Jr.: The radiorenogram in Experimental Hypertension. *Proc. Soc. Exp. Biol. and Med.* 112:1069-1073, 1963.
6. Blafox M, Owen CA, Jr., Brown AL, Jr.: Fine Structure of the Kidney in Experimental Renal Hypertension. *Mayo Clinic Proc.* 39:191-196, 1964.
7. Blafox MD, Merrill JP: Measurement of Renal Function in Man with Simplified Hippuran Clearance. *Nephron* 3:274-281, 1966.
8. Blafox MD, Hampers CL, Merrill JP, Constatine L: Anticoagulation Rebound Occurring After Regional Heparinization for Hemodialysis. *Trans. of the Am. Soc. for Artificial Int. Organs.* 12:207-209, 1966.
9. Blafox MD, Birbari A, Hickler R, Merrill JP: Peripheral Plasma Renin Activity in Renal Homotransplant Recipients. *New Eng. J. Med.* 275:1165-1168, 1966.
10. Lewis E, Blafox MD, Hickler R: Renin Secretion by the Denervated Kidney. *Brit. Med. J.* 2:1430-1431, 1966.
11. Hampers C, Blafox MD, Merrill JP: Anticoagulation Rebound After Hemodialysis. *New Eng. J. Med.* 275:776-778, 1966.
12. Blafox MD, Potchen E, Merrill JP: Measurement of Effective Renal Plasma Flow in Man by External Counting Methods. *J. Nucl. Med.* 8:77-85, 1967.
13. Blafox MD, Guttman RD, Merrill JP: Measurement of Renal Function in Rat with Single Injection Clearances. *Am. J. Physiol.* 212:629-632, 1967.
14. Blafox MD, Merrill JP: Evaluation of Renal Transplant Function by Iodohippurate Sodium <sup>131</sup>I. *JAMA* 202:575-578, 1967.
15. Blafox MD, Conroy MF: Measurement of Renal Mean Transit Time of Hippuran <sup>131</sup>I with External Counting. *J. Nucl. Biol. Med.* 12:107-116, 1968.
16. Freeman LM, Meng C, Blafox MD: Diagnosis of Arteriovenous Fistula of the Kidney with Renal Blood Flow Scintiphography. *Radiol.* 91:1189-1190, 1968.
17. Bianchi C, Blafox MD: <sup>131</sup>I-Hypaque and <sup>140</sup>La-DTPA for the Measurement of Glomerular Filtration Rate in Dog. *J. Nucl. Biol. Med.* 12:117-120, 1968.
18. Blafox MD, Lewis E, Jagger P, Lauer D, Hickler R, Merrill JP: Physiologic Responses of the Trans-planted Human Kidney: Sodium Regulation and Renin Secretion. *New Eng J Med.* 280:62-66, 1969.
19. Freeman LM, Goldman SM, Shaw RK, Blafox MD: Kidney Visualization with <sup>131</sup>I-ortho-iodohippurate in Patients with Renal Insufficiency. *J. Nucl. Med.* 10:545-549, 1969.

20. Siegel JH, Janis R, Alper JC, Schutte H, Robbins L, Blaurox MD: Disseminated Visceral Kaposi's Sarcoma: Appearance After Human Renal Homograft Operation. *JAMA* 207:1493-1496, 1969.
21. Freeman LM, Meng C, Bernstein RG, Blaurox MD: Rapid, Sequential Renal Blood Flow Scintiphography. *Radiol.* 92:918-923, 1969.
22. Blaurox MD, Conroy MF: Measurement of the Mean Transit Time of Hippuran <sup>131</sup>I, p. 20-24, Proc. of the First Intl. Symp. on Radioisotopes in Diagnosis of Diseases of the Kidneys and the Urinary Tract. Liege, June 1967. *Excerpta Med. Fdtn.* p. 189-193, July 1969.
23. Blaurox MD, Merrill JP: Renal Function Following Homotransplantation of the Kidney. Proc. of the First Intl. Symp. on Radioisotopes in the Diagnosis of Diseases of the Kidneys and the Urinary Tract. Liege, June 1967. *Excerpta Med. Fdtn.* p. 395-397, July 1969.
24. Strauss BS, Blaurox MD: Estimation of Residual Urine and Urine Flow Rates Without Urethral Catheterization. *J.Nucl.Med.* 11:81-84, 1970.
25. Blaurox MD, Cohen A: Single Injection Clearances of Iothalamate <sup>131</sup>I in the Rat. *Am.J. Physiol.* 218:542-544, 1970.
26. Blaurox MD, Fromowitz A, Gruskin A, Meng C, Elkin M: Validation of the Use of Xenon-133 to Measure the Intrarenal Distribution of Blood Flow. *Am.J.Physiol.* 219:440-444, 1970.
27. Blaurox MD, Fromowitz A, Lee H, Meng C, Elkin M: Renal Blood Flow and Renin Activity in Renal Venous Blood in Essential Hypertension. *Circ.Res.* 27:913-920, 1970.
28. Blaurox MD, Nash FD: Report of the U.S.-Japan Seminar on Control of Renin Secretion. *Jap.Heart J.* 11:506-511, 1970.
29. Freeman L, Meng C, Richter M, Blaurox MD: Patency of Major Renal Vascular Pathways Demonstrated by Rapid Blood Flow Scintiphography. *J.Urol.* 105:473-481, 1971.
30. Blaurox MD, Gruskin A, Sandler P, Goldman H, Edelmann CM, Jr., Ogwo J: Scintigraphy for Detection of Vesico-Ureteral Reflux in Children. *J.Pediatrics* 79:239-246, 1971.
31. Milstein D, Lee HB, Liang T, Blaurox MD: Glomerular Blood Flow Distribution in the Rat. Preliminary Observations. *Radionuclides in Nephrology, Proceeding of an Intl. Symposium*, Blaurox MD and Funck-Brentano JL (Eds), Grune & Stratton, New York, N.Y., 1972, p.17-20.
32. Blaurox MD, Lee HB, Liang T, Meng C: Intrarenal Blood Flow, Sodium Regulation and Renin Secretion in Hypertensive Man. *Radionuclides in Nephrology. Proceedings of an Intl. Symp.*, Blaurox MD and Funck-Brentano JL (Eds), Grune & Stratton, New York, N.Y., 1972, p.77-85.
33. Blaurox MD, Goodman A, Weseley S, Schechter H, Weinstein E: The Renin-Angiotensin System in Patients Receiving Chronic Hemodialysis, in *Control of Renin Secretion*, Assaykeen T (Ed), Academic Press, New York, N.Y., 1972, p. 193-207.
34. Chervu LR, Lory M, Liang T, Lee HB, Blaurox MD: Determination of Plasma Renin Activity by Radio-immunoassay. Comparison of Results from Two Commercial Kits with Bioassay. *J.Nucl.Med.* 13:806-810, 1972.
35. Silkans G, Jeck D, Earon J, Edelmann CM, Jr., Chervu LR, Blaurox MD, Spitzer A: Simultaneous Measurement of Glomerular Filtration Rate and Renal Plasma Flow Using Plasma Disappearance Curves. *J Pediatrics* 83:749-757, 1973.
36. Chervu LR, Novich I, Blaurox MD: Fluorotec: A New Bone Seeker. *Radiol.* 107:435-437, 1973.

37. Olbing H, Blafox MD, Aschinberg LC, Silkalns GI, Bernstein J, Spitzer A, Edelmann CM, Jr.: Postnatal Changes in Renal Glomerular Blood Flow Distribution in Puppies. *J.Clin.Invest.* 52:2885-2895, 1973.
38. The HDFP Cooperative Group. The Hypertension Detection and Follow-Up Program (U.S.A.). INSERM (l'Institut National de la Sante et de la Recherche Medicale) 21:185-194, 1973.
39. Fine L, Lee HB, Weber H, Goldsmith D, Blafox MD: The Effects of Catheterization of the Renal Artery on Renal Function in the Rat. *J.Applied Physiol.* 37:930-933, 1974.
40. Aschinberg L, Goldsmith D, Olbing H, Spitzer A, Edelmann CM, Jr., Blafox MD: Neonatal Changes in Renal Blood Flow Distribution in Puppies. *Am.J. Physiol.* 228:1453-1461, 1975.
41. Blafox MD, Lee HB, Milstein D: Renal Blood Flow Distribution in the Rat During Intraarterial Infusion of Vasoactive Agents. Radionuclides in Nephrology. Proceedings of the International Congress, zum Winkel K, Blafox MD, Funck-Brentano JL (Eds), Georg Thieme, Stuttgart, Germany, 1975, p. 9-13.
42. Goldsmith D, Drukker A, Spitzer A, Blafox MD, Edelmann CM, Jr.: Response of the Neonatal Canine Kidney to Acute Saline Expansion. Proceedings of the International Congress, zum Winkel K, Blafox MD, Funck-Brentano JL (Eds), Georg Thieme, Stuttgart, Germany, 1975, p. 45-51.
43. Drukker A, Lee HB, Edelmann CM, Jr., Blafox MD: Radioimmunoassay of Plasma Renin Activity in Small and Neonatal Animals, Normal Values, Developmental Patterns and Response to Acute Intravenous Saline Load. Proceedings of the International Congress, zum Winkel K, Blafox MD, Funck-Brentano JL (Eds), Georg Thieme, Stuttgart, Germany, 1975, p. 108-113.
44. Wassertheil-Smoller S, Bell B, Blafox MD: Computer Aided Management of Hypertensive Patients. *Medical Care.* 13:1044-1054, 1975.
45. Wassertheil-Smoller S, Blafox MD: Planning Case Finding Activities For a Community Hypertension - Control Program. *Bulletin of the New York Academy of Medicine* (52(6):648-656, 1976.
46. Blafox MD: Definition of the Dilemma of the Scope of Diagnostic Investigation in the Community Hypertension Program. *Bulletin of the New York Academy of Medicine* 52(6):671-679, 1976.
47. The Hypertension Detection and Follow-Up Program Cooperative Group: The Hypertension Detection and Follow-Up Program. *Prev. Med.* 5:207-215, 1976.
48. The Hypertension Detection and Follow-Up Program Cooperative Group: Blood Pressures Studies in Fourteen Communities: A Two Stage Screen for Hypertension. *JAMA* 237:2385-2391, 1977.
49. The Hypertension Detection and Follow-Up Program Cooperative Group, A Progress Report. *Circ. Res. Supp.* 40:1 106-1 109, 1977.
50. Chervu LR, Lee HB, Goyal Q, Blafox MD: Use of <sup>99m</sup>Tc Cu DTPA Complex as a Renal Function Agent. *J Nucl Med.* 18:62-66, 1977.
51. Koshy MC, Mickley D, Bourgoignie J, Blafox MD: Physiologic Evaluation of a New Antihypertensive Agent: Prazosin HCl. *Circulation* 55:533-537, 1977.
52. Chervu LR, Vallabhajosula SR, Blafox MD: Quality Control of the Technetium Labelled Lung Imaging Agents. *Int.J.Nucl.Med.& Biol.* 4:201-203, 1977.
53. Wassertheil-Smoller S, Bijur P, Blafox MD: An Evaluation of the Utility of High Blood Pressure Detection Fairs. *Am.J.Public Health* 68(8):768-770, 1978.
54. Levine R, Blafox MD: Hyperreninemia During Renal Transplantation. *Nephron* 22:226-231, 1978.

55. Koenigsberg M, Novich I, Lory M, Blafox MD: Limits of Sensitivity of Radiopertechnetate Flow Studies in the Detection of Asymmetrical Renal Perfusion. *Contributions to Nephrology*. II:73-79, 1978.
56. The Hypertension Detection and Follow-Up Program Cooperative Group. Variability of Blood Pressure and the Results of Screening in the Hypertension Detection and Follow-Up Program. *J.Chronic Disease* 31:651-667, 1978.
57. The HDFP Cooperative Group. Mild Hypertensives in the HDFP. (Prepared by Polk BF, Apostolides A, Blafox MD, Borhani N, Cutter G, Daugherty S, Lewin A). *Annals of the New York Academy of Sciences*. 304:254-266, 1978.
58. The Hypertension Detection and Follow-Up Program Cooperative Group. Patient Participation in a Hypertension Control Program. *JAMA* 239:1507-1514, 1978.
59. The Hypertension Detection and Follow-Up Program Cooperative Group. Therapeutic Control of Blood Pressure in the Hypertension Detection and Follow-Up Program (Prepared by Blafox MD, Curb D, Finnerty F, Kralius A, Polk BF, Tyler M). *Prev. Med.* 8:2-13, 1979.
60. Blafox MD, Wassertheil-Smoller S:Improving Blood Pressure Normalization: Follow-Up of Hypertension Screening and Methodologies. *N.Y.S. J. Med.* 79(2):231-235, 1979.
61. Ongseng F, Chervu LR, Kogan SJ, Factor SM, Levitt, SB, Blafox MD: Static Testicular Imaging Utilizing  $^{201}\text{Tl}$ . *Investigative Urology* 16:451-452, 1979.
62. The Hypertension Detection and Follow-Up Program Cooperative Group. Five-Year Findings of the Hypertension Detection and Follow-Up Program. I. Reduction in Mortality of Persons with High Blood Pressure, Including Mild Hypertension. *JAMA* 242:2562-2571, 1979.
63. The Hypertension Detection and Follow-Up Program Cooperative Group. Five Year Findings of the Hypertension Detection and Follow-Up Program. II. Mortality by Race, Sex and Age. *JAMA* 242:2572-2577, 1979.
64. Illoreta A, Blafox MD: The Natural History of Post-Biopsy Renal Arteriovenous Fistula: A Ten Year Follow-Up. *Nephron* 24:250-253, 1979.
65. Goldsmith D, Drukker A, Blafox MD, Spitzer A,Edelmann C,Jr.:Hemodynamic and Excretory Response of the Neonatal Canine Kidney to Acute Volume Expansion. *Am.J. Physiol.* 237:392-397, 1979.
66. The Hypertension Detection and Follow-Up Program Group. Fifth Hahnemann International Symposium on Hypertension, January 1977. *Hypertension Determinants, Complications and Intervention*. Grune & Stratton, New York, N.Y., 1979.
67. McAfee J, Gagne G, Atkins A, Kirchner P, Reba R, Blafox MD: Biological Distribution and Excretion of DTPA labelled with  $^{99\text{m}}\text{Tc}$  and  $^{111}\text{In}$ . *J.Nucl.Med.* 20:1273-1278, 1979.
68. Drukker A, Goldsmith D, Spitzer A, Edelmann C,Jr., Blafox MD: The Renin Angiotensin System in Newborn Dogs: Developmental Patterns and Response to Acute Saline Loading. *Pediatric Res.* L4:304-307, 1980.
69. Sherman RA, Blafox MD: Obstructive Uropathy in Patients with Nonvisualization on Renal Scan. *Nephron* 25:82-86, 1980.
70. LeJemtel T, Keung E, Ribner H, Davis R, Wexler J, Blafox MD, Sonnenblick E: Sustained Beneficial Effects of Oral Amrinone on Cardiac and Renal Function in Patients with Severe Congestive Heart Failure. *Am.J. Cardiology* 45:123-129, 1980.
71. Sherman R, Blafox MD: Clinical Significance of Non-Visualization with  $^{131}\text{I}$  Hippuran Renal Scan. *Radionuclides in Nephrology*, Georg Thieme, Stuttgart, Germany, 1980, p. 235-239.

72. Scharf S, Wexler J, Longnecker R, Blaurox MD: Non-Invasive Measurement of Myocardial Function in Chronic Hemodialysis. In Radionuclides in Nephrology, Georg Thieme, Stuttgart, Germany, 1980, p. 231-234.
73. Frater R, Wakayama S, Oyama T, Oka Y, Becker R, Desai P, Blaurox MD: Pulsatile Cardiopulmonary Bypass: Failure to Influence Hemodynamics of Hormones. *Circulation* 62(SI):19-25, 1980.
74. Wexler J, Kalika V, Strom J, Blaurox MD: Computer Assisted ECG Gated Scintillation Probe Measurement of Left Ventricular Ejection Fraction: A New Position Algorithm. *Nucl. Med. Communications* 1:273-281, 1980.
75. Kalika V, Bard R, Illoreta A, Freeman L, Heller S, Blaurox MD: Prediction of Renal Functional Recovery After Relief of Upper Urinary Tract Obstruction. *J. Urol.* 126:301-305, 1980.
76. Heller SL, Wexler JP, Powell M, Blaurox MD: Deadtime Measurements with a Multihole Phantom: Concise Communication. *J.Nucl.Med.* 22:62-64, 1981.
77. Blaurox MD, Wexler J, Sherman R, Scharf S, Sonnenblick E, Strom J, Lee HB: Left Ventricular Ejection Fraction and its Response to Therapy in Essential Hypertension. *Nephron* 28:112-117, 1981.
78. Blaurox MD, Ross L, Koshy K, Lee HB: The Physiologic Effects of Prazosin HCL: Consequences of Combination Therapy. *Nephron* 29:85-89, 1981.
79. Yee C, Lee HB, Blaurox MD: Tc-99m DMSA Renal Uptake: Influence of Biochemical and Physiologic Factors. *J.Nucl.Med.* 22:1054-1058, 1981.
80. Oka Y, Wakayama S, Oyama T, Orkin L, Becker R, Blaurox MD, Frater R: Cortisol and Antidiuretic Hormone Responses to Stress in Cardiac Surgical Patients. *Canad. Anaesth. Soc.J.* 28:334-338, 1981.
81. Blaurox MD: Efficacy of Methyldopa in the Older Patient in Long-Term Treatment of Hypertension with Methyldopa. *J. Cardiovascular Pharm.* 3:SI04-SI08, 1981.
82. The Hypertension Detection and Follow-Up Program Cooperative Group: Five-Year Findings of the Hypertension Detection and Follow-Up Program. III Reduction in Stroke Incidence Among Persons with High Blood Pressure. *JAMA* 247:633-638, 1982.
83. Chervu S, Chervu LR, Goodwin PN, Blaurox MD, Freeman L, Milstein, D: Thyroid Uptake Measurements with I-123: Problems and Pitfalls. *J.Nucl.Med.* 23:667-670, 1982.
84. Heller SL, Goodwin PN, Scharf SC, Hardoff R, Blaurox MD: A Dual Collimator Design for Beat-to-Beat Measurement of Cardiac Performance Employing an Anger Camera. *J.Nucl.Med.* 23:836-839, 1982.
85. Chervu LR, Vallabhajosyula B, Mani J, Chun SB, Blaurox MD: Stannous Ion Quantitation in <sup>99m</sup>Tc-Radiopharmaceutical Kits. *Eur. J. Nucl. Med.* 7:291-293, 1982.
86. Wassertheil-Smoller S, Langford H, Blaurox MD, Oberman A, Babcock C, Hotchkiss J: Rate of Hypertension Return After Withdrawal of Prolonged Antihypertensive Therapy. *Clin. Sci.* 63:423s-425s, 1982.
87. The Hypertension Detection and Follow-Up Program Cooperative Group: The Effect of Treatment on Mortality in "Mild" Hypertension: Results of the Hypertension Detection and Follow-Up Program. *New Eng. J. Med.* 307:976-980, 1982.
88. Blaurox MD, Constable AR: Antique Hazards: A Latter Day Encounter with Radium. *J. Nucl Med* 24:79-82, 1983
89. Lee HB, Wexler JP, Scharf SC, Blaurox MD: Pharmacologic Alternations in Tc-99m Binding by Red Blood Cells: Concise Communication. *J. Nucl. Med.* 24:397-401, 1983.



90. Castronuovo J, Wexler JP, Davis R, Strom J, Blaurox MD: Validation of Systolic Time Intervals Determined with an ECG Gated Scintillation Probe. *Nucl.Med. Comm.* 4:232-239, 1983.
91. Oberman A, Blaurox MD, Entwisle G, Harrist R (On Behalf of the HDFP Cooperative Group): Baseline Chest Radiographic Characteristics of the Hypertensive Participants. *Hypertension* 5(S IV):190-205, 1983.
92. Scharf SC, Lee HB, Wexler John P and Blaurox MD: Cardiovascular Consequences of Primary Antihypertensive Therapy with Prazosin Hydrochloride. *Am. J. Card.* 53:32A-36A, 1984.
93. Chervu S, Chervu LR, Vallabhajosyula B, Milstein DM, Shapiro KM, Shulman K, Blaurox MD: Quantitative Evaluation of Cerebrospinal Fluid Shunt Flow. *J. Nucl. Med.* 25:91-95, 1984.
94. Blaurox MD, Fine E, Lee HB, Scharf SC: The Role of Nuclear Medicine in Clinical Urology and Nephrology. *J. Nucl. Med.* 25:619-625, 1984.
95. The Hypertension Detection and Follow-Up Program Cooperative Group: Five Year Findings of The Hypertension Detection and Follow-Up Program: Effect of Stepped Care Treatment on the Incidence of Myocardial Infarction and Angina Pectoris. *Hypertension (Supplement I)*. 6:I-198/I-206, 1984.
96. The Hypertension Detection and Follow-up Program Cooperative Group: Five Year Findings of the Hypertension Detection and Follow-Up Program: Mortality by Race-Sex and Blood Pressure Level. A Further Analysis. *Jrl.Comm. Health* (9)314-327, 1984.
97. Chervu LR, Sundoro BM, Blaurox MD: Tc-99m-Labeled P-Aminohippuric Acid Analog: A New Renal Agent. (Concise Communication) *J.Nucl. Med.* 25:III3-III5, 1984.
98. The Hypertension Detection and Follow-Up Program Cooperative Research Group: The Effect of Antihypertensive Drug Treatment on Mortality in the Presence of Resting Electrocardiographic Abnormalities at Baseline: The HDFP Experience. *Circulation* 70(6):996-1003, 1984.
99. Thomas SR, Atkins HL, McAfee JG, Blaurox MD, Fernandez M, Kirchner PT, Reba RC (Task Group of the Medical Internal Radiation Dose Committee, The Society of Nuclear Medicine): Radiation Absorbed Dose from Tc-99m Diethylenetriaminepentaacetic Acid (DTPA). *J. Nucl. Med.* 25:503-505, 1984.
100. Heller SL, Scharf SC, Hardoff R, Blaurox MD: Cinematic Display of Respiratory Organ Motion with Impedance Techniques. *J. Nucl. Med.* 25:II27-II3I, 1984.
101. Langford HG, Blaurox MD, Oberman A, Hawkins CM, Curb JD, Cutter GR, Wassertheil-Smoller S, Pressel S, Babcock C, Abernethy JD, Hotchkiss J, Tyler M: Return of Hypertension After Withdrawal of Prolonged Antihypertensive Therapy, Effect of Weight Loss, Sodium Reduction and Baseline Factors. *Transactions of the Association of American Physicians*, 1984. 97:190-196.
102. Langford HG and (by invitation) Blaurox MD, Oberman A, Hawkins CM, Curb JD, Cutter GR, Wassert Smoller S, Pressel S, Babcock C, Abernethy JD, Hotchkiss J, Tyler M, Caggiula A, Wing RR: Does Effective Antihypertensive Therapy Partially "Cure" Hypertension? *Transactions of the American Clinical and Climatological Association*, 1984. 96:III-II9.
103. Blaurox MD, Langford HG, Oberman A, Hawkins CM, Wassertheil-Smoller S, Cutter GR: Effect of Dietary Change on the Return of Hypertension After Withdrawal of Prolonged Antihypertensive Therapy (DISH). *Jrl of Hypertension* 2(3):179-18I, 1984.
104. Davis L, Wexler JP, Rabinowitz A, LeJemtel T, Lee MK, Chervu LR, Blaurox MD: Data Acquisition Using a Scintillation Detector Interfaced to a Personal Micro-computer. *J. Nucl. Med.* 26:85-8, 1985.
105. Langford HG, Blaurox MD, Oberman A, Hawkins CM, Curb JD, Cutter GR, Wassertheil-Smoller S, Pressel S, Babcock C, Abernethy JD, Hotchkiss J, Tyler M: Dietary Therapy Slows the Return of Hypertension After Stopping Prolonged Medication. *JAMA* 253(5):657-664, 1985.

106. Wassertheil-Smoller S, Langford HG, Blaurox MD, Oberman A, Hawkins M, Levine B, Cameron M, Babcock C, Pressel S, Cagguila A, Cutter G, Curb D, Wing R: Effective Dietary Intervention in Hypertensives: Sodium Restriction and Weight Reduction. *J. Amer. Diet. Assoc.* 85(4):423-432, 1985.
107. The Hypertension Detection and Follow-Up Program Cooperative Group: Five-Year Findings of the Hypertension Detection and Follow-Up Program: Prevention and Reversal of Left Ventricular Hypertrophy with Antihypertensive Drug Therapy. *Hypertension* 7(1):105-112, 1985.
108. Lewin A, Blaurox MD, Castle H, Entwisle G, Langford H, On Behalf of the Hypertension Detection and Follow-Up Program: Apparent Prevalence of Curable Hypertension in the Hypertension Detection and Follow-Up Program. *Archives of Internal Medicine* 145:424-427, 1985.
109. Lee HB, Blaurox MD: Blood Volume in the Rat. *J. Nucl. Med.* 25:72-76, 1985.
110. Lee HB, Blaurox MD: Mechanism of Renal Concentration of Technetium-99m Glucoheptonate. *J.Nucl. Med.* 26:1308-1313, 1985.
111. Blaurox MD, Langford HG, Oberman A, Hawkins CM, Curb JD, Cuttler GR, Wassertheil-Smoller S, Pressel S, Babcock C, Abernethy JD, Hotchkiss J, Tyler M: The Dietary Intervention Study of Hypertension (DISH). *Cardiovascular Reviews and Reports* 6:1036-1052, 1985.
112. The Hypertension Detection and Follow-Up Program Cooperative Research Group: Mortality Findings for Stepped Care and Referred Care Participants in the Hypertension Detection and Follow-Up Program, Stratified by Other Risk Factors. *Prev. Med.* 14:312-335, 1985.
113. Shim C, Chun KJ, Williams MH Jr., Blaurox MD: Positional Effects on Distribution of Ventilation in Chronic Obstructive Pulmonary Disease. *Annals of Int. Med.* 105:346-350, 1986.
114. Wassertheil-Smoller S, Blaurox MD, Langford HG, Oberman A, Cutter G, Pressel S: Prediction of Response to Sodium Intervention for Blood Pressure Control. *J. of Hypertension* 4(S5):S343-S346, 1986.
115. Blaurox MD: Should Mild Hypertension beTreated: Yes. *J. of Hypertension* 4(S5):S541-S544, 1986.
116. Lee HB, Blaurox MD: Renal Functional Changes After Angiotensin Converting Enzyme Inhibition or Nitroprusside in Hypertensive Rats. *J. of Hypertension* 4(S5):S266-S268, 1986.
117. Borhani NO, Blaurox MD, Oberman A, Polk F: incidence of Coronary Heart Disease and Left Ventricular Hypertrophy in the Hypertension Detection and Follow-Up Program. *Prog. in Cardiovascular Dis.* 29(3-S1):55- 62, 1986.
118. Zuckier LS, Axelrod MS, Wexler JP, Heller SL, Blaurox MD: The Implications of Decreased Performance of New Generation Gamma-Cameras on the Interpretation of <sup>131</sup>I-Hippuran Renal Images. *Nuclear Medicine Communications* 8:49-61, 1987.
119. Davis BR, Langford HG, Blaurox MD, Curb JD, Polk BF, Shulman NB: The Association of Postural Changes in Systolic Blood Pressure and Mortality in Persons with Hypertension: The Hypertension Detection and Follow-Up Program Experience. *Circulation* 75(2):340-346, 1987.
120. Langford HG, Blaurox MD, Borhani NO, Curb JD, Molteni A, Schneider KA, Pressel S: Is Thiazide-Produced Uric Acid Elevation Harmful? Analysis of Data from the Hypertension Detection and Follow-Up Program. *Arch. Intern. Med.* 147:645-649, 1987.
121. Fine EJ, Axelrod M, Gorkin J, Saleemi K, Blaurox MD: Measurement of Effective Renal Plasma Flow: A Comparison of Methods. *J.Nucl. Med.* 28:1393-1400, 1987.

122. Hypertension Detection and Follow-Up Program Cooperative Group. Education Level, and Five Year All-Cause Mortality in the Hypertension Detection and Follow-Up Program (HDFP). *Hypertension* (9):641-646, 1987.
123. Kim CK, Fine EJ, Blafox MD: Nonvisualization of Both Kidneys With I-131 Orthoiodohippurate Scintigraphy. *Sem. Nucl. Med.* 18(1):68-70, 1988.
124. Blafox MD: Radioactive Artifacts: Historical Sources of Modern Radium Contamination. *Sem. Nucl. Med.* 18(1):46-64, 1988.
125. Cooper SP, Hardy RJ, Labarthe DR, Hawkins CM, O'Brian Smith E, Blafox MD, Entwisle G, Maxwell M, Cooper CJ (On Behalf of the Hypertension Detection and Follow-Up Cooperative Group): The Relation Between Degree of Blood Pressure Reduction and Mortality Among Hypertensives in the Hypertension Detection and Follow-Up Program. *Am. J. Epidemiol.* 127:387-403, 1988.
126. Hypertension Detection and Follow-Up Program Cooperative Group: Persistence of Reduction in Blood Pressure and Mortality of Participants in the Hypertension Detection and Follow-Up Program. *JAMA* 259:2113-2122, 1988.
127. Blafox MD, Freeman LM: Renewed Role of Nuclear Medicine in Renovascular Hypertension. *Urol. Rad.* 10:35-38, 1988.
128. The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and Design of a Randomized Clinical Trial on Prevention of Stroke in Isolated Systolic Hypertension. *J. Clin. Epidemiol.* 41(12):1197-1208, 1988.
129. Wadler S, Tai K, Chervu LR, Rafii S, Landau L, Blafox MD, Wiernik PH: Iodine-131 MIBG Scintigraphy in small Cell Lung Cancer. *Eur. J. Nucl. Med.* 15:108-110, 1989 (Short Communication).
130. Lee HB, Blafox MD: 99m-Tc MAG-3 Clearances After Captopril In Experimental Renovascular Hypertension. *J. Nucl. Med.* 30(5):666-671, 1989.
131. Davis BR, Blafox MD, Hawkins CM, Langford HG, Oberman A, Swencionis C, Wassertheil-Smoller S., Wylie-Rosett J, Zimbaldi N., for the TAIM Research Group. Trial of Antihypertensive Interventions and Management: Design, Methods, and Selected Baseline Results. *Controlled Clinical Trials* 10(1):11-30, 1989.
132. Langford HG, Rockhold RW, Smoller SW, Oberman A, Davis BR, Blafox MD: Effect of Weight Loss on Thiazide Produced Erectile Problems in Men. *Transactions of the American Clinical and Climatological Association* 101:190-194, 1989.
133. Shulman NB, Ford CE, Dallas Hall W, Blafox MD, Simon D, Langford HG, Schneider KA: Prognostic Value of Serum Creatinine and the Effect of Treatment of Hypertension on Renal Function. Results from The Hypertension Detection and Follow-Up Program. *Hypertension* 13(5):I-80 - I-93, 1989
134. Blafox MD: Cost-Effectiveness of Nuclear Medicine Procedures in Renovascular Hypertension. *Sem. Nucl. Med.* 19(2):116-121, 1989.
135. Oberman A, Wassertheil-Smoller S, Langford H, Blafox MD, Davis BR, Blaszkowski T, Zimbaldi N, Hawkins CM, for the TAIM Research Group. Pharmacologic and Nutritional Treatment of Mild Hypertension: Changes in Cardiovascular Risk Status. *Annals of Int. Med.* 112(2):89-95. 1990.
136. Zuckier LS, Finkelstein M, Kreutzer ER, Stone PL, Freed SZ, Bard RH, Blafox MD, Freeman LM: Technetium-99m Antimony Sulfide Colloid Lymphoscintigraphy of the Prostate by Direct Transrectal Injection. *Nucl. Med. Communications* 11(9):589-596, 1990.

137. Wassertheil-Smoller S, Langford HG, Yamori Y, Blafox MD, Oberman A, Davis B, Nara Y, Wylie-Rosett J, Zimbaldi N: Estimation of Protein Intake: Comparison of Dietary and Urinary Excretion. *J Cardiovasc Pharmacol* 16(S8):S28-S31, 1990.
138. Hull DM, Peskin CS, Rabinowitz AM, Wexler JP, Blafox MD: The Derivation and Verification of a Nonstationary Optimal Smoothing Filter for Nuclear Medicine Image Data. *Physics in Med. & Biol.* 35(12):1641-1662, 1990.
139. Wassertheil-Smoller S, Blafox MD, Oberman A, Davis BR, Swencionis C, O'Connell Knerr M, Hawkins CM, Langford HG, for the TAIM Research Group: Effect of Antihypertensives on Sexual Function and Quality of Life: The TAIM Study. *Annals of Int. Med.* 114(8):613-620, 1991.
140. Langford HG, Davis BR, Blafox MD, Oberman A, Wassertheil-Smoller S, Hawkins CM, Zimbaldi N, for the TAIM Research Group: Effect on Drug and Diet Treatment of Mild Hypertension on Diastolic Blood Pressure. *Hypertension* 17(2):210-217, 1991.
141. SHEP Cooperative Research Group: Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons with Isolated Systolic Hypertension: Final Results of the Systolic Hypertension in the Elderly Program (SHEP). *JAMA* 265(4):3255-3264, 1991.
142. Wassertheil-Smoller S, Davis BR, Oberman A, Blafox MD, Langford HG, Wylie-Rosett J, Hawkins CM, Zimbaldi N. TAIM Study: Sex-Race Differences in Effects of Diet and Drugs on Cardiovascular Risk. *Cardiovascular Risk Factors* 1:427-435, 1991.
143. Fine EJ, Blafox MD On Behalf of the Albert Einstein College of Medicine/Cornell University Medical Center Collaborative Hypertension Group: The Einstein/Cornell Collaborative Protocol to Assess Efficacy and Methodology in Captopril Scintirenoigraphy. *Am J. Hypertens* 4:716S-720S, 1991.
144. Gale B, Zhang C, Lee HB, Heller S, Blafox MD: The Effect of Captopril on Glucoheptonate Uptake in Experimental Renal Artery Stenosis, *Nucl Med Comm* 13:110-113, 1992.
145. Wassertheil-Smoller S, Oberman A, Blafox MD, Davis BR, Langford HG: The TAIM Study: Final Results with Regard to Blood Pressure, Cardiovascular Risk, and Quality of Life. *Am J Hyper* 5:37-44, 1992.
146. Blafox MD, Langford HG, Lee HB, Davis BR, Oberman A, Wassertheil-Smoller S: Renin Predicts Diastolic Blood Pressure Response to Nonpharmacologic & Pharmacologic Therapy. *JAMA* 267(9):1221-1225, 1992.
147. Wassertheil-Smoller S, Blafox MD, Oberman A, Langford HG, Davis BR, Wylie-Rosett J: The Trial of Antihypertensive Interventions and Management (TAIM) Study. Adequate Weight Loss Alone and Combined With Drug Therapy in the Treatment of Mild Hypertension. *Arch. Int. Med.* 152:131-136, 1992.
148. Davis BR, Oberman A, Blafox MD, Wassertheil-Smoller S, Morton Hawkins C, Cutler JA, Zimbaldi, N and Langford HG: Effect of Antihypertensive Therapy on Weight Loss. *Hypertension* 19:393-399, 1992.
149. Lee HB, Blafox MD: Renal Functional Response to Captopril During Diuretic Therapy. *J Nucl Med* 33:739-743, 1992.
150. Blafox MD: Cardiovascular Care in the Elderly Round Table: Clinical Trials in the Elderly. *High Blood Pressure* 1:126-128, 1992.
151. Wassertheil-Smoller S, Blafox MD, Oberman A, Davis BR, Swencionis C, O'Connell Knerr M, Hawkins CM, Langford HG for the TAIM Research Group: The TAIM Study: Antihypertensive Therapy's Effect on the Quality of Life. *Cardiology Board Review* 9:65-72, 1992.
152. Davis BR, Blafox MD, Oberman A, Wassertheil-Smoller S, Zimbaldi N, Cutler JA, Kirchner K, Langford HG, for the TAIM Research Group: Reduction in Long-Term Antihypertensive Medication Requirements:

Effects of Weight Reduction by Dietary Intervention in Overweight Persons with Mild Hypertension. Archives in Int. Med. 153:1773-1782, 1993.

153. SHEP Cooperative Research Group: Implications of the Systolic Hypertension in the Elderly Program. Hypertension 21(3):335-343, 1993.
154. Wylie-Rosett J, Wassertheil-Smoller S, Davis BR, Langford HG, Blafox MD, Oberman A, Jennings S, Hataway H, Stern J, Zimbaldi N: Trial of Antihypertensive Intervention and Management: Greater Attainment of the 6 Month Intervention Goals for Weight Loss Than Na/K Modification. J of the Am Dietetic Association 93:408-414, 1993.
155. Thaler L, Wassertheil-Smoller S, Blafox MD, Oberman A, Langford HG: Effect of Withdrawal of Antihypertensive Drug on Depressive Mood. Am J Hypertens 6:1055-1062, 1993.
156. Wassertheil-Smoller S, Davis BR, Breuer B, Oberman A, Blafox MD, Chang CJ, Langford HG: Differences in Precision of Dietary Estimates Among Different Population Subgroups. Annals of Epidemiology 3 (6):619-628, 1993.
157. Ho GYF, Blafox MD, Wassertheil-Smoller S, Oberman A, Langford H: Plasma Renin Predicts Success of Antihypertensive Drug Withdrawal. Amer J Hypertens 7:679-684, 1994.
158. Davis BR, Oberman A, Blafox MD, Wassertheil-Smoller S, Zimbaldi N, Kirchner K, Wylie-Rosett J, Langford HG: Lack of Effectiveness of a Low Sodium and High Potassium Diet in Reducing Antihypertensive Medication Requirements in Overweight Persons with Mild Hypertension (TAIM). Amer J Hypertens 7:926-932, 1994.
159. Wassertheil-Smoller S, Davis BR, Oberman A, Blafox MD, Kirchner K: Gender Differences and Similarities in Effects of Nonpharmacologic Approaches to the Treatment of Mild Hypertension. Am. J. Human Biology 7:195-201, 1995.
160. Zuckier LS, Korupolu GR, Gladshteyn M, Goldstein R, Ricciardi R, Goodwin P, Melman A, Blafox MD: A Non-Imaging Scintillation Probe for Measurement of Penile Hemodynamics. J. Nucl. Med. 36:2345-2351, 1995.
161. Blafox MD, Middleton ML, Bongiovanni J, Davis, B: Cost Efficacy of the Diagnosis and Therapy of Renovascular Hypertension. J. Nucl. Med. 37:171-177, 1996.
162. Fine EJ, Blafox MD, Blumenfeld J, Laragh J, Chun KJ, Heller S, Bongiovanni J: Exercise Renography in Untreated Subjects with Essential Hypertension. J. Nucl. Med. 37:838-842, 1996.
163. Blafox MD: Becquerel and the Discovery of Radioactivity: Early Concepts. Sem Nucl Med 26(3):145-154, 1996.
164. Blafox MD, Aurell M, Bubeck B, Fommei E, Piepsz A, Russell C, Taylor A, Thomsen HS, Volterrani D: Report of the Radionuclides in Nephrourology Committee on Renal Clearance. J. Nucl. Med. 37:1883-1890, 1996.
165. Taylor A, Jr, Nally J, Aurell M, Blafox MD, Dondi M, Dubovsky E, Fine E, Fommei E, Geyskes G, Granerus G, Kahn D, Morton K, Oei HY, Russell C, Sfakianakis G, Fletcher J: Consensus Report on Ace Inhibitor Renography for the Detection of Renovascular Hypertension. Radionuclides in Nephrourology, Ninth International Symposium. J. Nucl. Med. 37:1876-1882, 1996.
166. Li Y, Lee HB, Blafox MD: Single-Sample Methods to Measure GFR with Technetium-99m-DTPA. J. Nucl. Med. 38:1290-1295, 1997.
167. SHEP Cooperative Research Group: Prevention of Heart Failure by Antihypertensive Drug Treatment in Older Persons with Isolated Systolic Hypertension. JAMA 278(3):212-216, 1997.
168. Blafox MD, Middleton ML, Bongiovanni J, Davis BR: A Cost Analysis of the Detection of Renovascular Hypertension: The Einstein/Cornell Collaborative Hypertension Study in, Radionuclides in Nephrourology,

Proceedings of the 9th International Symposium, Santa Fe, NM, May, 1995, Taylor A, Nally JV, Thomsen H (Eds), Society of Nuclear Medicine, Reston VA, 1997, p. 37.

169. Blafox MD, Fine EJ, Heller SH, Hurley J, Jagust M, Yi L, Mann S, Pickering T, Rackson M, Rottman GA, Sarkar S, Zanzonico P, Zhang CG: Captopril Renography in Hypertensive Patients with Diminished Renal Function: The Einstein/Cornell Collaborative Hypertension Study in, Radionuclides in Nephrourology, Proceedings of the 9th International Symposium Santa, Fe, NM, May, 1995, Taylor A, Nally JV, Thomsen H (Eds), Society of Nuclear Medicine, Reston VA, 1997, p. 72.
170. Blafox MD, Fine EJ, Heller SH, Hurley J, Jagust M, Yi L, Mann S, Pickering T, Rackson M, Rottman GA, Sarkar S, Zanzonico P, Zhang CG: Simultaneous OIH and DTPA Captopril Renography in Essential Hypertension: The Einstein/Cornell Collaborative Hypertension Study in, Radionuclides in Nephrourology, Proceedings of the 9th International Symposium, Santa Fe, NM, May, 1995, Taylor A, Nally JV, Thomsen H (Eds), Society of Nuclear Medicine, Reston VA, 1997, p. 77.
171. Li Y, Blafox MD, Fine EJ: Effect of Captopril on Renal Mean Transit Time in Patients with Essential Hypertension: The Einstein/Cornell Collaborative Hypertension Study in, Radionuclides in Nephrourology, Proceedings of the 9th International Symposium, Santa Fe, NM, May, 1995, Taylor A, Nally JV, Thomsen H (Eds), Society of Nuclear Medicine, Reston VA, 1997, p. 82.
172. Blafox MD, Fine EJ, Heller S, Hurley J, Jagust M, Li Y, Mann SJ, Pickering TG, Zanzonico P, Zhang CG. The Einstein/Cornell Collaborative Hypertension Group: Prospective Study of Simultaneous Orthoiodohippurate and Diethylenetriaminepentaacetic Acid Captopril Renography. *J. Nucl. Med.* 39:522-528, 1998.
173. Taylor AT, Fletcher JW, Nally JV, Blafox MD, Dubovsky EV, Fine EJ, Kahn D, Morton KA, Russell D, Sfakianakis GN, Aurell M, Dondi M, Fommei E, Geyskes G, Granerus G, Oei HY: Procedure Guideline for Diagnosis of Renovascular Hypertension. *J. Nucl. Med.* 39:1297-1302, 1998.
174. Moran JK, Lee HB, Blafox MD: Optimization of Urinary FDG Excretion During PET Imaging. *J. Nucl. Med.* 40:1352-1357, 1999.
175. Piepsz A, Blafox MD, Granerus GG, Majd M, O'Reilly P, Rosenberg AR, Rossleigh MA, Sixt R: Consensus on Renal Cortical Scintigraphy in Children With Urinary Tract Infection. *Seminars in Nuclear Medicine*, 2:160-174, 1999.
176. Prigent A, Cosgriff P, Gates FG, Granerus G, Fine EJ, Kazua I, Peters M, Piepsz A, Rehling M, Rutland M, Taylor A: Consensus Report on Quality Control of Quantitative Measurements of Renal Function Obtained From the Renogram: International Consensus Committee From the Scientific Committee of Radionuclides in Nephrourology. *Seminars in Nuclear Medicine* 2: 146-159, 1999.
177. Fine JF, Li Y, Blafox MD: Parenchymal Mean Transit time Analysis of <sup>99m</sup>Tc-DTPA Captopril Renography. *J. Nucl. Med.* 41:1627-1631, 2000
178. Bar-Shalom R, Valdivia AY, Blafox MD: PET Imaging in Oncology. *Seminars in Nucl Med* . 31(3):150-185, 2000.
179. Lee HB, Diamond BA, Blafox MD: In-Vivo Detection of Deposition of Radiolabeled Lupus Anti-Kidney Antibody and its Inhibition by Soluble Antigen. *J. Nucl. Med.* 42:138-140, 2001
180. Fine EJ, Blafox MD: Renal Scintigraphy: An Update. *Applied Radiology* 19-25, 2001.
181. Blafox MD, Gottschalk A: Whose Liability Is It Anyway? *J. Nucl. Med.* 42:12, 1729, 2001
182. Khandani AH, Keller SM, Blafox MD: <sup>18</sup>F-Fluorodeoxyglucose Positron Emission Tomography: False-Positive Lung Scan. *Seminars in Nuclear Medicine* 32(3):212-213, 2002
183. Zhao DS, Valdivia AY, Blafox MD: <sup>18</sup>F-Fluorodeoxyglucose Positron Emission Tomography in Small-Cell Lung Cancer. *Seminars in Nuclear Medicine.* 32(4):272-275, 2002.

184. Moadel RM, Nguyen AV, Lin EY, Lu P, Mani J, Blaurox, MD, Pollard JW, Dadachova, E: Positron emission tomography agent 2-deoxy-2 (<sup>18</sup>F) fluoro-D-glucose has a therapeutic potential in breast cancer. *Breast Cancer Res* 5:R199, August, 2003.
185. Isasi CR, Moadel RM, Blaurox MD: A Meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. *Breast Cancer Research and Treatment* 90:105-112, 2005.
186. Moadel RM, Weldon RH, Katz EB, Lu P, Mani J, Stahl M, Blaurox MD, Pestell RG, Charron MJ, Dadachova E, Positherapy: Targeted Nuclear Therapy of Breast Cancer with <sup>18</sup>F-2-Deoxy-2-Fluoro-D-Glucose. *Cancer Research* 65(3):698-702, 2005.
187. Isasi CR, Lu P, Blaurox MD: A Meta-analysis of <sup>18</sup>F-2-Deoxy-2Fluor-D-Glucose Positron Emission Tomography in the Staging and Restaging of Patients with Lymphoma. *Cancer* 104:1066-1074, 2005.
188. Khandani AH, Isasi CR, Blaurox MD: Intra-individual Variability of Cardiac Uptake on Serial Whole Body 18-F-FDG PET. *Nucl Med Communications* 26:787-791, 2005.
189. Jana S, Blaurox MD: Nuclear Medicine Studies of the Prostate, Testes, and Bladder. *Seminars Nucl Med* 36:51-72, 2006.
190. Jana S, Zhang T, Milstein D, Isasi, C, Blaurox MD: FDG-PET and CT Characterization of Adrenal Lesions in Cancer Patients. *Eur J Nucl Med* 33:29-35, 2006.
191. Khandani AH, Whitney KD, Keller SM, Isasi CR, Blaurox MD: Sensitivity of FDG PET, GLUT 1 Expression and Proliferative Index in Bronchioloalveolar Lung Cancer. *Nucl Med Communications* 128:173-177, 2007.
192. Blaurox, MD: A Brief History of the Radionuclides in Nephrourology Group (ISCORN). *Seminars Nucl Med* 38:2-38:2-8, 2008.
193. Durand E, Blaurox MD, Britton KE, Carlsen O, Cosgriff P, Fine E, Fleming J, Nimmon C, Piepsz A, Prigent A, Samal M: International Scientific Committee of Radionuclides in Nephrourology (ISCORN) Consensus on Renal Transit Time Measurements. *Seminars Nucl Med* 38:82-102, 2008.
194. Guha C, Blaurox MD, Alfieri A, Kalnicki S: Tumor Biology Guided RT Treatment Planning: The Gross Tumor Volume (GTV) versus the Functional Tumor Volume (BTV). *Seminars Nucl Med* 38:105-113, 2008
195. Blaurox, MD, Constable AR: The Sandglass and the Pulse. *Bulletin of the Scientific Instrument Society*. No. 96, 18-19, 2008.
196. Fine EJ, Miao W, Koba W, Volek JS, Blaurox MD: <sup>18</sup>F-2, Fluoro 2, deoxy-glucose uptake in rodent heart and brain after chronic dietary carbohydrate restriction. *Nucl Med Commun* 30(9):675-680, 2009
197. Das BC, Mani S, Blaurox MD: Design and Synthesis of 3-phenyl-2H-benzo(b)(1,4) oxazine containing PET imaging agents for hypoxia. *J Nucl Med* 50:660-661, 2009.
198. Shapoval A, Chamarthy M, Blaurox MD, Freeman LM: Marrow Visualization on Renal Scintigraphy: An Often Overlooked Finding In Azotemic Patients. *J Nucl Med* 52:901-904, 2011.
199. Ma HY, Blaurox MD: An Unusual Urine Leak with Urolithiasis. *Clinical Nucl Med*,11(38), 2013.
200. Remer EM, Papanicolaou N, Casalino DD, Bishoff JT, Blaurox MD, Coursey CA, Dighe M, Eberhardt SC, Goldfarb S, Harvin HJ, Heilbrun ME, Leyendecker JR, Nikolaidis P, Oto, A, Preminger GM, Raman SS, Sheth S, Vikram R, Weinfeld RM: ACR Appropriateness Criteria® on Renal Failure. *Amer J of Med* Nov;127(11):1041-1048, 2014

201. Seedah B, Heilbrun ME, Remer EM, Casalino DD, Beland MD, Bishoff JT, Blaufox MD, Coursey CA, Goldfarb S, Harvin HJ, Nikolaidis P, Preminger GM, Raman SS, Sahni A, Vikram R, Weinfeld RM: ACR Appropriateness Criteria® Indeterminate Renal Mass. *J Am Coll Radio* Apr;12(4):333-41, 2015.
202. Heilbrun ME, Remer EM, Casalino DD, Beland MD, Bisoff JT, Blaufox MD, Coursey CA, Goldfarb S, Harvin HJ, Nikolaidis P, Preminger GM, Raman SS, Sahni A, Vikram R, Weinfeld RM: ACR Appropriateness Criteria Indeterminate Renal Mass. *J Am Coll Radiol* 12(4):333-341 April 2015.
203. Vikram R, Beland MD, Blaufox MD, et al. ACR Appropriateness Criteria Renal Cell Carcinoma Staging. *J Am Coll Radiol* 2016;13:518-525
204. Taylor AT, Brando DC, de Palma D, Blaufox MD, Durand E, Erbas B, Grant SF, Hilson AJW, Morsing A. SNMMI Procedure Standard/EANM Practice Guideline for Diuretic Renal Scintigraphy in Adults With Suspected Upper Urinary Tract Obstruction. 2018: 48, 377–390
205. Blaufox MD, De Palma D, Li Y, Prigent A, Sama MI, Santos A, Szabo Z, Taylor A, Testanera G, Tulchinsky M: The SNMMI and EANM Practice Guideline for Renal Scintigraphy in Adults(2018) 45: 2218. <https://doi.org/10.1007/s00259-018-4129-6>



## **THESIS**

Blaufox MD: Studies of Renal Function and Experimental Hypertension, Mayo Foundation and the University of Minnesota, July 1963. Submitted in partial fulfillment for the requirements of a degree of Doctor of Philosophy in Medicine.

## **CHAPTERS IN BOOKS, AND REVIEWS AND EDITORIALS IN TEXTBOOKS AND JOURNALS**

1. Blaufox MD: Radioisotope Assessment of Steroid Hormone Secretion. *Rad. Clinic of N. Am.* 5:231-238, 1967.
2. Blaufox MD: Physical Concepts of Hemodialysis, in Hampers and Schupak Long Term Hemodialysis. Grune & Stratton, New York, N.Y., 1967, p. 12-23.
3. Blaufox MD: Dynamic Function Studies in Nuclear Medicine. Yearbook of Nuclear Medicine, Vol. 3, Quinn J, III (Ed), Yearbook Medical Publisher, Chicago, Illinois, 1968, p. 7-27.
4. Blaufox MD: Evaluation of Renal Function with Radioisotopes. *Urology Digest* 7:19-28, 1968.
5. Blaufox MD: Systemic Arterial Hypertension in Pediatric Practice. *Pediatric Clinics of N.A.* 18:577-594, 1971.
6. Blaufox MD: Systemic Arterial Hypertension. Pediatrics, Barnett H (Ed), Appleton Century Crofts, New York, N.Y., 1972, p. 980-988.
7. Blaufox MD: Measurement of Renal Function with Radioactive Materials. Evaluation of Renal Function and Disease with Radionuclides, Blaufox MD (Ed), S. Karger, Basel, Switzerland, 1972, p. 9-20.
8. Blaufox MD: Methods for Measurement of the Renal Blood Flow. Evaluation of Renal Function and Disease with Radionuclides, Blaufox MD (Ed), S. Karger, Basel, Switzerland, 1972, p. 78-84.
9. Blaufox MD: Compartment Analysis of the Radiorenogram and Kinetics of <sup>131</sup>I Hippuran. Evaluation of Renal Function and Disease with Radionuclides, Blaufox MD (Ed), S. Karger, Basel, Switzerland, 1972, p. 107-123.
10. Blaufox MD: Determination of Residual Urine. Evaluation of Renal Function and Disease with Radionuclides, Blaufox M (Ed), S. Karger, Basel, Switzerland, 1972, p. 138-143.
11. Blaufox MD, Freeman LM: Study of Renal Disorders with Radionuclides. Clinical Uses of Radionuclides: Critical Comparison with Other Techniques. USAEC Report Conf-71101, Goswitz F, Andrews G, Viamonte M (Eds), 1972, p. 431-446.
12. Blaufox MD: Nuclear Medicine and Renal Disease. *Hospital Practice* 7:137-144, 1972.
13. Blaufox MD, Freeman LM: Radionuclide Techniques for the Evaluation of Diseases of the Urinary Tract in Children. *Seminars in Nucl. Med.* 3:27-53, 1973.
14. Blaufox MD, Silkans G, Jeck D, Spitzler A, Chervu LR, Edelmann CM, Jr.: Renal Function Studies in Pediatrics. Pediatric Nuclear Medicine, James E, Wagner H, Cooke R (Eds), W.B. Saunders, Phila., PA., 1974, p. 314-334.
15. Chervu LR, Freeman LM, Blaufox MD: Radiopharmaceuticals for Renal Studies. *Seminars in Nuclear Medicine* 4:3-22, 1974.
16. Koenigsberg M, Blaufox MD, Freeman LM: Traumatic Injuries of the Renal Vasculature and Parenchyma. *Seminars in Nuclear Medicine* 4:117-133, 1974.
17. Blaufox MD: Principles of Renal Evaluation with Radionuclides in Rein et Foie Maldies de la Nutrition, *Journées Internationales de Nephrologie* 16B:17-34, 1974.

18. Blafox MD, Himmelstein S: Dynamic Function Studies: Rapid Sequence Imaging. Clinical Scintillation Imaging, Freeman LM, Johnson P (Eds), Grune & Stratton, 1975, p. 175-204.
19. Blafox MD, Chervu LR, Freeman LM: Radiopharmaceuticals for Quantitative Study of Renal Function. Radiopharmaceuticals, Subramanian G (Ed). The Society of Nuclear Medicine, 1975, p. 385-396.
20. Blafox MD, Bell EG: General Principles of Renal Evaluation with Radionuclides. Diagnostic Nuclear Medicine, Gottschalk A, Potchen EJ (Eds), Williams and Wilkins, Baltimore, Md., 1976, p. 469-475.
21. Bell EG, Blafox MD: Clinical Applications of Renal Imaging. Diagnostic Nuclear Medicine, Gottschalk A, Potchen EJ (Eds), Williams and Wilkins, 1976, p. 476-491.
22. Blafox MD, Bell EG: The Use of Radionuclides in Diseases of the Lower Urinary Tract. Diagnostic Nuclear Medicine, Gottschalk A, Potchen EJ (Eds), Williams and Wilkins, 1976, p. 592-596.
23. Blafox MD: The Role of Nuclear Medicine Procedures in Clinical Nephrology: Current Clinical Status and Future Directions. La Ricerca Clinica Lab. 6:160, 1976.
24. Koenigsberg M, Freeman L, Blafox MD: Radionuclide and Ultrasound Evaluation of Renal Morphology and Function. Pediatric Kidney Disease, Edelmann C, Jr. (Ed), Little, Brown & Company, Boston, Massachusetts, 1978.
25. Blafox MD, Freeman LM: The Application of Nuclear Medicine in Nephrology and Urology. Radiology of the Urinary System, Elkin M (Ed), Little Brown & Company, Boston, Massachusetts, 1980, p. 1140-1188.
26. Scharf S, Wexler J, Longnecker R, Blafox MD: Cardiovascular Disease in Patients on Chronic Hemodialytic Therapy. Progress in Cardiovascular Disease 22:343-356, 1980.
27. Blafox MD: Comments for the Panel Session on Clearance Determinations from Single Plasma Samples. Radionuclides in Nephrology, Georg Thieme, Stuttgart, Germany, 1980, p. 72-73.
28. Blafox MD, Chervu LR: Analysis of Structure-Activity Relationships of Renal Imaging Agents. Proceedings of the Symposium on Radiopharmaceuticals: Structure-Activity Relationships, Spencer RP (Ed), Grune and Stratton, Inc., New York, N.Y. 1980, p. 557-572.
29. Wexler J, Steingart R, Blafox MD: Physiologic Interventions in Nuclear Medicine. Seminars in Nuclear Medicine 11(2):68-79, 1981.
30. Steingart R, Wexler J, Blafox MD: Pharmacologic Intervention in Cardiovascular Nuclear Medicine. Seminars in Nuclear Medicine 11(2):30-86, 1981.
31. Blafox MD: Segmental Evaluation of Renal Function with Radionuclides, in Dialogues in Pediatric Urology, Ehrlich RM (Ed), William J. Miller Associates, Inc., Pearl River, New York, 1982, p. 3-4.
32. Chervu LR, Blafox MD: Renal Secretion and Filtration Studies, in Cellular Function Using Radiotracers, Billingham MW (Ed), CRC Press, Inc., Boca Raton, Florida, 1982, p. 145-179.
33. Chervu LR, Blafox MD: Renal Radiopharmaceuticals - An Update. In Seminars in Nuclear Medicine, Freeman LM, Blafox MD (Eds), Grune and Stratton, New York, N.Y. 12:224-245, 1982.
34. Scharf SC, Blafox MD: Radionuclides in the Evaluation of Urinary Obstruction, In Seminars in Nuclear Medicine, Freeman LM, Blafox MD (Eds), Grune and Stratton, New York, N.Y., 12:254-264, 1982.
35. Blafox MD, Chervu LR, Goodwin P, Wolfson L, Bridger WH, Scheuer J: Positron Emission Tomography: A Review and Prospectus. Einstein Quarterly 1:61-68, 1982.
36. Blafox MD, Kalika V, Scharf SC, Milstein DM: Applications of Nuclear Medicine in Genitourinary Imaging. Urologic Radiology 4:155-164, 1982.

37. Blafox MD: Radiation Reactions and Injuries in Section Entitled "Disorders Due to Physical Agents" in the Merck Manual (14th Edition), Merck, Sharp and Dohme Research Laboratories, Rahway, NJ., 1982, p. 2128-2134.
38. Blafox MD: Diagnostic Use of Radioisotopes in Section Entitled "Special Subjects" in the Merck Manual (14th Edition), Merck, Sharp and Dohme Research Laboratories, Rahway, NJ., 1982, p. 2163-2172.
39. Blafox MD, On Behalf of The HDFP Cooperative Group: An Overview of the Results and Implications of the Hypertension Detection and Follow-Up Program, in Proceedings of the International Symposium on Hypertension Control in the Community, Tel Aviv, Israel, November 1982. John Libbey Publishers Ltd. London, England, 1983.
40. Oberman A, Blafox MD, Entwisle G, Harrist R (On Behalf of the HDFP Cooperative Group): Baseline Chest Radiographic Characteristics of the Hypertensive Participants. Supp. IV Hypertension 5:IV-190-IV-205, 1983.
41. Wassertheil-Smoller S, Langford HG, Blafox MD, Oberman A, Hawkins M: Diuretics and Salt Restriction in Blood Pressure Control, In Nutrition and Drugs, Winick M (Ed), John Wiley & Sons, Inc., New York, 1983.
42. Blafox MD: Commentary on Chapter 7 "Isotopic Renography in Renovascular Hypertension" by Tauxe WN, In Renovascular Hypertension, Stanley JC, Ernst CB, Fry WJ (Eds), W.B. Saunders Company, Philadelphia, 1984, p. 133-134.
43. Blafox MD: Diuretic Renography and Other Interventions in Urinary Tract Disease, In Interventional Nuclear Medicine, Spencer RP (ED), Grune and Stratton, New York, 1984, p. 519-544.
44. Fine EJ, Scharf SC, Blafox MD: The Role of Nuclear Medicine in Evaluating the Hypertensive Patient, In Nuclear Medicine Annual 1984, Freeman LM, Weissmann HS (Eds), Raven Press, New York, 1984, p. 23-79.
45. Fine EJ, Blafox MD: Quantitation of Renal Function. Current Concepts in Diag. J. Nucl. Med. 1:12-17, 1984.
46. Blafox MD: Quantification of the Radionuclide Image: Theoretical Considerations and the Role of the Computer, In Freeman and Johnson Clinical Radionuclide Imaging (3rd edition), Freeman LM (Ed), Grune and Stratton, Inc., Orlando, Florida, 1984, p. 261-313.
47. Fine EJ, Axelrod M, Blafox MD: Physiologic Aspects of Diagnostic Renal Imaging. Seminars in Nephrology 5(3):188-207, 1985.
48. Scharf SC, Blafox MD: Radionuclides in the Evaluation of Urinary Obstruction, In Nuclear Medicine in Nephrology and Urology, Tauxe WN (Ed), Appleton-Century-Crofts, Norwalk, CT, 1985, p. 191-206.
49. LaBarthe C, Blafox MD, Carey R, Gifford R, Kirkendall W, Moser R, Smith WM, Viteri F: An Epidemiological Approach to Describing Risk Associated with Blood Pressure Levels. Final Report of the Working Group on Risk and High Blood Pressure. Hypertension 7:641-651, 1985.
50. Rafii S, Bhargava KK, Chervu LR, Wadler S, Blafox MD: Advances in Nuclear Medicine: Scintigraphic Localization of Endocrine Neoplasms. Einstein Quarterly: J. Biol. Med. 3:129-135, 1985.
51. Blafox MD, Fine EJ: Nephrologic Applications of Radionuclides, In Nuclear Medicine in Urology and Nephrology, O'Reilly PH, Testa H, Shields R (Eds), Butterworth, London, 1986.
52. Blafox MD: The Current Status of Renal Radiopharmaceuticals. In Contributions to Nephrology, S. Karger AG, Basel, Switzerland, 1986.

53. Blaufox, MD, On Behalf of The HDFP Cooperative Group: Implications of the Hypertension Detection and Follow-up Program. In, Progress in Cardiovascular Diseases, Grune & Stratton, Inc. (Eds), New York, NY. 1986; 29(3) Suppl 1, p.3-10.
54. Blaufox MD: Radiation Reactions and Injuries, In Section Entitled "Disorders Due to Physical Agents", Merck Manual (15th Edition), Merck, Sharp and Dohme Research Laboratories, Rahway, NJ., 1987, p. 2347- 2388.
55. Lee HB, Blaufox MD: Renal Function Changes After Converting Enzyme Inhibition or Nitroprusside in Hypertensive Rats. In Contributions to Nephrology, Blaufox MD, Bischof-Delaloye A (Eds), S. Karger, Basel, 1987, p. 87-94.
56. Blaufox MD, Lee HB: The Role of Radionuclides in the Differential Diagnosis of Renovascular Hypertension. In New Procedures in Nuclear Medicine, Spencer R (Ed), CRC Press, Inc., Boca Raton, 1989, pp 41-49.
57. Fine EJ, Blaufox MD: Urological Applications of Radionuclides. In Clinical Urography, Pollack H (Ed), W.B. Saunders, Philadelphia, 1989, p. 518-557.
58. Blaufox MD: The Role of Nuclear Medicine: A Historical Perspective. In, Evaluation of Renal Function and Disease with Radionuclides: The Upper Urinary Tract, Blaufox MD (Ed), S.Karger, Basel, Switzerland, 1989, p. 2-11.
59. Blaufox MD: Measurement of Renal Function with Radioactive Materials. In, Evaluation of Renal Function and Disease with Radionuclides: The Upper Urinary Tract, Blaufox MD (Ed), S.Karger, Basel, Switzerland, 1989, p. 12-27.
60. Chervu LR, Blaufox MD: Radiopharmaceuticals for the Measurement of Glomerular Filtration Rate and Renal Plasma Flow. In, Evaluation of Renal Function and Disease with Radionuclides: The Upper Urinary Tract, Blaufox MD (Ed), S. Karger, Basel, Switzerland, 1989, p. 28-59.
61. Blaufox, MD: Methods for Measurement of the Renal Blood Flow. In, Evaluation of Renal Function and Disease with Radionuclides: The Upper Urinary Tract, Blaufox MD (Ed), S. Karger, Basel, Switzerland, 1989, p. 84-97.
62. Lee HB, Gale B, Blaufox MD: Paradoxical Increased Glucoheptonate Uptake in Experimental Renovascular Hypertension. In Radionuclides in Nephro-Urology, Contributions to Nephrology, Blaufox MD, Hollenberg NK, Raynaud C (Eds), Karger, Basel, 1990, vol 79, p. 170-175.
63. Blaufox MD, Fine EJ: The Role of Nuclear Medicine Techniques for Evaluating Hypertensive Disease. In Hypertension: Pathophysiology, Diagnosis and Management, Laragh JH, Brenner B M (Eds), Raven Press, New York, 1990, p. 1509-1534.
64. Moser M, Blaufox MD, Freis E, Gifford Jr. RW, Kirkendall W, Langford H, Shapiro A, Sheps S: Who Really Determines your Patient's Prescriptions. *JAMA* 265:498-500, 1991.
65. Blaufox MD: Procedures of Choice in Renal Nuclear Medicine. *J Nucl Med* 32:1301-1309, 1991.
66. Blaufox MD: The Role and Rationale of Nuclear Medicine Procedures in the Differential Diagnosis of Renovascular Hypertension. *Nucl. Med. Biol. (Int. J. Radiat. Appl. Instrum. Part B, 18(6):583-587, 1991.*
67. Blaufox MD: Captopril Renography: Considerations in the Selection of Radiopharmaceuticals, Provocative Agents and Hypertensive Subjects. *Am J Hyper* 4:675S-677S, 1991.
68. Blaufox MD, Dubovsky EV, Hilson AJW, Taylor A Jr., de Zeeuw R: Report of the Working Group on Determining the Radionuclide of Choice. Captopril Consensus Conference, Cleveland. *Am J Hyper* 4:747S-748S, 1991.

69. Labarthe DR, Blafox MD, Smith WM, Lacy CR, Schnaper H, LaBaw F, Mascioli S, Davey J, Lakatos E: Part 5: Baseline Blood Pressure and Pulse Rate Measurements. *Hypertension*, Supplement II, 17(3): 63-76, 1991.
70. Blafox MD: Radionuclide Techniques for the Diagnosis of Urinary Tract Disease. In Diagnostic Techniques in Renal Disease, Narins RG (Ed), Churchill Livingstone Inc., New York, 1992, p. 305-330.
71. Blafox MD: Radiation Reactions and Injuries, in Section Entitled "Disorders Due to Physical Agents", Merck Manual (16th Edition), Merck, Sharp and Dohme Research Laboratories, Rahway, NJ., 1992, p. 2513-2519.
72. Blafox MD: Nuclear Medicine, in Section Entitled "Special Subjects", The Merck Manual, (16th Edition), Merck Sharp & Dohme Research Laboratories, Rahway NJ., 1992, p. 2547-2552.
73. Blafox MD, Kaplan NM: Diagnostics and Techniques. *Current Opinion in Nephrology and Hypertension*, 1:249-251, 1992.
74. The SHEP Cooperative Research Group: Isolated Systolic Hypertension in the Elderly. In Focus on Hypertension (Clinical Cardiology Digest Series), Frohlich E (Ed), 1S:5-12, 1993.
75. Middleton ML, Bongiovanni JA, Blafox MD: Evaluation of Renovascular Hypertension. *Current Opinion in Nephrology and Hypertension*, 2(6):940-948, 1993.
76. Blafox, MD: Renal Imaging. Hypertension Primer, Izzo JL, Black HR, Taubert KA (Eds), American Heart Association, Dallas, Texas, 1993, Chapter 16, p. 257-259.
77. Davis BR, Blafox MD, Oberman A, Wassertheil-Smoller S, Zimbaldi N, Cutler JA, Kirchner K, Langford HG: Reduction in Long-Term Antihypertensive Medication Requirements. *Arch Intern Med*, 153:1773-1782, 1993.
78. Sheps SG, Blafox MD, Nally JV, Textor, SC: Radionuclide Scintigraphy in the Evaluation of Patients with Hypertension. *J. of the Am College of Cardiology*, 21(3):1-2, 1993.
79. Blafox, MD: Diagnostics and Techniques. *Current Opinion in Nephrology and Hypertension*, (2):926-927, 1993.
80. Blafox MD, Fotopoulos A, Lee HB, Lynn R: Effect of Residual Urine on Apparent Renal Clearance in Patients with Reduced Function, in Radionuclides in Nephrourology, O'Reilly PH, Taylor A, Nally JV (Eds), Field & Wood Medical Periodicals, Inc., Blue Bell PA, 1994, Chapter 24, p. 163-167.
81. Blafox MD: Current Concepts in the Diagnosis of Urinary Tract Infection. *Current Opinion in Nephrology and Hypertension*, 3:629-630, 1994.
82. Blafox, MD: Should the Role of Captopril Renography Extend to the Evaluation of Chronic Renal Disease? *J Nucl Med* 35(2):254-256, 1994.
83. Smoller SW, Blafox MD, Davis BR, Kirchner K, Langford HG, Oberman A: The Trial of Antihypertensive Interventions and Management (TAIM). *Nieren-und Hochdruckkrankheiten*, Supplement, p. S22-S27, 1994.
84. Blafox, MD: Measurement of Renal Function. *Current Opinion in Nephrology and Hypertension*, (4):503-504, 1995.
85. Blafox MD, Middleton ML, Fine EJ: Role of Nuclear Medicine Techniques for Evaluating Hypertensive Disease. In Hypertension: Pathophysiology, Diagnosis and Management, Second Edition, Laragh JH, Brenner BM (Eds), Raven Press, New York, 1995, p. 2005-2036.
86. Middleton ML, Blafox MD: Renal Scintigraphy: Practical Applications. *Applied Radiology*, 25(6):6-16, 1996.

87. Chervu LR, Blafox MD: Radiopharmacy of Renal Imaging and Clearance Agents, Autoradiography and Dosimetry of Renal Agents, in, Kidney, Hor G, Pabst HW (Eds), Gustav Fisher Verlag, Stuttgart, Jena, New York, 1996, p.19-50.
88. Blafox MD: It's Time to Stop Crying and Do Something. J Nucl Med 38(6):19N, 1997.
89. Blafox MD: Radiation Injury, in, The Merck Manual of Medical Information Home Edition, Berkow R (Ed), Merck Research Laboratories, Whitehouse Station, NJ, 1997, p.1340-1343.
90. Blafox MD: Radiation Reactions and Injuries, in section Entitled "Disorders Due to Physical Agents", The Merck Manual (17th Edition)(Centennial Edition), Merck, Sharp and Dohme Research Laboratories, Rahway, NJ. 1999, p. 2443-2447.
91. Blafox MD, Moran JK: New and Future Trends in Radiopharmaceuticals, in Medical Radiology, Trends in Contrast Media, Thomsen HS, Muller RN, Mattrey RF (Eds), Springer-Verlag, Berlin, Germany, 1999, 37:457-467.
92. Blafox MD: Past, Current and Future Developments of Nuclear Medicine Techniques: The Kidneys and Hypertension. Guest Editor, Q J Nucl Med 46:245-248, 2002.
93. Moadel RM, Blafox MD, Freeman LM: The Role of Positron Emission Tomography in Gastrointestinal Imaging. Gastroenterol Clin N Am. 31:841-861, 2002.
94. Liu Y, Blafox MD: Use of Radionuclides to Study Renal Function, in Methods in Molecular Medicine: Renal Disease: Techniques and Protocols. Michael S. Goligorsky (Ed), Humana Press, Totowa, NJ., 2003.
95. Blafox MD: Editorial Comments: Transport of Technetium-99m MAG<sub>3</sub> via Rat Renal Organic Anion Transporter 1. J Nucl Med, 45(1): 86-88, 2004.
96. Blafox MD: Renovascular Disease: Present and Future Developments in Functional and Molecular Imaging, in, Functional Imaging in Nephrourology. Michael Dunitz (Ed), 2006.
97. Li Y, Blafox MD: Renal Imaging in Nuclear Medicine, Krauz BJ, Czerni J, Drzezg D, Schwaiger M (Eds) Springer-Verlag, Germany 2014. (published online only)
98. Blafox MD: Forward:: Introductory Comments: Radionuclides and Hybrid Bone Imaging. Fogelman I, Granerus G, Van der Wal HJ. Springer-Verlag, Berlin, Heidelberg, Germany, 2012
99. Blafox, MD. Editorial Comments: Renal background correction and measurement of split renal function: The challenge. Eur J Nucl Med.Mol Imaging, 43:548-549, 2016

M. DONALD BLAUFOX, M.D., PH.D.

ABSTRACTS

1. Blafox M, Owen CA Jr., Brown AL Jr.: Renal Fine Structure in Experimental Hypertension. Fed Proc 22:256, 1963.
2. Blafox M, Merrill JP: Compartmental Analysis of Hippuran <sup>131</sup>I Renogram in Man. Fed Proc 24:405, 1965.
3. Blafox M, Potchen J: Measurement of Effective Renal Plasma Flow in Man by External Counting Methods. Clin Res 13:302, 1965.
4. Guttman R, Blafox M, Merrill JP: A Method for Determining Renal Function in the Rat Using Ortho-iodo-hippuran <sup>125</sup>I. Fed Proc 25:265, 1966.
5. Blafox MD, Birbari A, Hickler R, Merrill JP: Plasma Renin Levels in Hypertensive Renal Allograft Recipients. Clin Res 14:371, 1976.
6. Lewis E, Blafox MD, Jagger P, Laufer D, Qureshi E, Merrill JP: Sodium Balance in the Human Renal Transplant. J Clin Invest 45:1040, 1966.
7. Conroy M, Blafox M: Theoretical Basis for Estimating the Hippuran <sup>131</sup>I Renal Transit Time. J Nucl Med 7:359, 1966.
8. Blafox M, Conroy M: Hippuran <sup>131</sup>I Renal Transit Time in Man. J Nucl Med 7:358, 1966.
9. Blafox M, Merrill JP: Evaluation of Renal Homotransplant Function with Hippuran Clearances. Intl. Cong. of Nephrol. Abstracts, 1966, p. 160.
10. Lewis E, Blafox MD, Jagger P, Laufer D, Hickler R, Merrill JP: Sodium Homeostasis in the Denervated Human Kidney. Intl. Cong. of Nephrol. Abstracts, 1966, p. 231.
11. Blafox M, Conroy M: Hippuran <sup>131</sup>I Renal Transit Time in Man. Acta Urologica Belgica 35:33, 1967.
12. Blafox M: Evaluation of Renal Homotransplant Function with Hippuran Clearance. Acta Urologica Belgica 35:334, 1967.
13. Blafox M, Gruskin A, Katz M, Meng C, Elkin M: Clinical Assessment of Renal Blood Flow with <sup>133</sup>Xe. J Nucl Med 9:304, 1968.
14. Strauss B, Blafox MD: Radioisotopic Estimation of Residual Urine Without Urethral Catheterization. J Nucl Med 9:304, 1968.
15. Blafox MD, Fotino S: Renin Activity in Essential Hypertension. Clin Res 42:424, 1969.
16. Blafox MD, Fromowitz A, Meng C, Lee HB, Elkin M: Renal Blood Flow and Renin Secretion. Clin Res 42:425, 1969.
17. Blafox MD, Fromowitz A, Meng C, Lee HB, Elkin M: Renal Hemodynamics and Renin Activity in Benign Essential and Accelerated Hypertension. Proc of the Int Cong Nephrol, 1969, p. 308.
18. Blafox MD, Lee HB, Schechter H, Eschwark, Weingstein E: Renin Activity, Renin Substrate, and Renin Inhibitor in Hemodialysis Patients. Clin Res 18:495, 1970.
19. Fotino S, Blafox MD: Renin Activity and Catecholamine Excretion in Parkinsonism. Clin Res 18:499, 1970.

20. Freeman LM, Meng C, Richter M, Blaurox MD: Patency of Renal Vascular Pathways. Demonstrated by Rapid Blood Flow Scintigraphy. *J Nucl Me.* 11:321, 1970.
21. Blaurox M, Gruskin A, Sandler P, Owgo J, Goldman H, Edelmann CM, Jr.: Detection of Ureteral Vesical Reflux in Children with <sup>99m</sup>Tc Pertechnetate. *J Nuc. Med* 11:622, 1970.
22. Olbing H, Aschinberg L, Silkans G, Liang T, Edelmann CM, Jr., Blaurox MD: Postnatal Changes in Renal Blood Flow Distribution in Puppies. *Proc Amer Soc Neph* 1971, p. 58.
23. Milstein DM, Lee HB, Linag T, Blaurox MD: A Practical Method for Evaluation of Rat Glomerular Blood Flow Distribution. *J Nucl Med* 13:454-455, 1972.
24. Chervu LR, Blaurox MD, Eckelman WC, Richard P: Sn-117m Complexes for Skeletal Imaging. *J Nucl Med* 13:781, 1972.
25. Aschinberg LC, Goldsmith DI, Obling H, Hardy MA, Spitzer A, Edelmann CM, Jr., Blaurox MD: Neonatal Changes in Renal Blood Flow Distribution in Puppies. *Ped Res* 7:183, 1973.
26. Wassertheil-Smoller S, Bell B, Blaurox MD: Computer Aided Patient Management. Programs and Abstracts, APHA Annual Meeting, November 1973.
27. Koenigsberg M, Novich I, Lory M, Freeman LM, Blaurox MD: Detection of Asymmetrical Renal Perfusion by Radiopertechnetate Angiography. *J Nucl Med* 15:507, 1974.
28. Blaurox M: Normalization of Blood Pressure in Stepped Care Participants of the Hypertension Detection and Follow-Up Program (HDFP). *Circ* 50(4), Supplement III:148, 1974.
29. Chervu LR, Goyal Q, Blaurox MD: Technetium 99m Cu HEDSPA A New Skeletal Imaging Agent. *J Nucl Med* 16:520, 1975.
30. Koshy MC, Bourgoignie J, Blaurox MD: Physiological Evaluation of Prazosin: A New Antihypertensive Agent. *Kidney Intl* 8(6):440, 1975.
31. LeJemtel T, Hellman C, Elkayam U, Strom J, Blaurox MD, Frishman W, Ribner H, Sonnenblick E: Hemodynamic and Renal Response to Oral Hydralazine Therapy in Severe Heart Failure. *Circulation* 56,III-9, 1977.
32. Wexler JP, Strom J, Sonnenblick E, Blaurox MD: Validity of a Probe Technique for Ejection Fraction Determination. *J Nucl Med* 19:704, 1978.
33. Blaurox MD, Illoreta F, Heller S, Bard R, Freeman LM: Evaluation of Renal Functional Reserve with Cortical Regions of Interest. *J Nucl Med* 20:620, 1979.
34. Chervu LR, Robbins EB, Huq SS, Blaurox MD: In-Vivo and In-Vitro Studies of <sup>99m</sup>Tc HIDA Uptake. *J Nucl Med* 20:655, 1979.
35. The Hypertension Detection and Follow-Up Program Cooperative Group: Description and Comparison of the Role of Medical Therapists Within and Between Clinical Centers of the Hypertension Detection and Follow-Up Program (HDFP). *Preventive Medicine* 8:175, 1979.
36. Robbins EB, Chervu LR, Blaurox MD: Studies on the Accumulation of Radiopharmaceuticals in Injured Tissues. *Am J Radiol* 132:490, 1979.
37. Yee C, Lee HB, Blaurox MD: The Effect of Various Pathophysiologic Conditions on the Excretion and Renal Localization of <sup>99m</sup>Tc Dimercaptosuccinic Acid (DMSA). *J Nuc. Med* 21(6):P40, 1980.
38. Ganz WI, Wexler JP, Rabinowitz AM, Brenner AI, Steingart R, Blaurox MD: Methods of Improving the Precision of Left Ventricular Volume and Ejection Fraction Determinations. *J Nucl Med* 21(6):P48, 1980.



39. Wexler JP, Rabinowitz AM, Ganz WI, Yee C, Blafox MD: Automated Batch Processing of Radionuclide Angiograms. *J Nucl Med* 21(6):P72, 1980.
40. Fine E, Wexler JP, Heller S, Scharf S, Blafox MD: Models for Attenuations Corrected Ventricular Volumes. *J Nucl Med* 22(6):P29, 1981.
41. Chervu LR, Castronuovo JJ, Huq SS, Milstein DM, Blafox MD: Alterations in Red Cell Tagging with Sulfonamides. *J Nucl Med* 22(6):P70, 1981.
42. Chervu LR, Huq SS, Joseph JA, Chun SB, Blafox MD: Medication Induced Changes in Biodistribution of Radiopharmaceuticals. *J Nucl Med* 22(6):P72, 1981.
43. Chervu S, Chervu LR, Vallabhajosyula B, Shapiro KM, Milstein DM, Shulman K, Blafox MD: Quantitative Evaluation of Cerebrospinal Fluid Shunt Flow. *J Nucl Med* 22(6):P89, 1981.
44. Chervu S, Chervu LR, Goodwin PN, Milstein DM, Freeman LM, Blafox MD: Problems and Pitfalls in the Use of I-123 for Thyroid Uptake Measurements. *Med Physics* 8:739, 1981.
45. Lee HB, Wexler JP, Scharf SC, Blafox MD: Effect of Prazosin and Captopril on <sup>99m</sup>Tc Binding to Red Blood Cells. *J Nucl Med* 23:P57, 1982.
46. Heller SL, Scharf SC, Goodwin PN, Hardoff R, Blafox MD: Beat to Beat Measurement of Cardiac Performance with an Anger Camera Employing a Dual Collimator Design. *J Nucl Med* 23:P59, 1982.
47. Curb D, Langford H, Blafox MD, Borhani N, Chakrin A: Thiazide produced uric acid elevations do not cause renal damage. *Clin Res* 30:509A, 1982.
48. Byun KJC, Milstein DM, Lutzker LG, Heller SL, Blafox MD: Sensitivity of 8lm Krypton Ventilation Imaging as a Function of Body Position. *J Nucl Med* 23(5):P42, 1982.
49. Blafox MD, Smoller S, Maxwell M, et al: Prognostic Significance of Baseline Stressed Renin Activity (PRA) in the HDFP. Proceedings of the 37th Annual Fall Conference and Scientific Sessions of the Council for High Blood Pressure Research of the American Heart Association, September 1983, Cleveland, Ohio.
50. Blafox MD, Smoller S, Lee HB, Langford HG: Long Term Changes in Peripheral Renin Activity (PRA). Proceedings of the 37th Annual Fall Conference and Scientific Sessions of the Council for High Blood Pressure Research of the American Heart Association, September 1983, Cleveland, Ohio.
51. Ford, CE, Langford B, Blafox MD: Is Hypertension Worse in Blacks? Comparison of Creatinine levels at Equal Blood Pressure: Effect of Potassium for the Hypertension Detection and Follow-up Program. *Clin Res* 32:844A, 1984.
52. Lee HB, Blafox MD: Tc-99m Glucoheptonate (GHA) Renal Uptake: Influence of Biochemical and Physiologic Factors. *J Nucl Med* 25(5):P75, 1984.
53. Fine EJ, Gorkin J, Bank N, Saleemi K. Blafox MD: Radionuclide Measurement of Renal Function: A Comparison of Methods. Proceedings of the 31st Annual Meeting of The Society of Nuclear Medicine. *J Nucl Med* 25(5):P76, 1984.
54. Davis BR, Langford HG, Blafox MD, Polk BF, Shulman NB, Curb JD (On Behalf of the Hypertension Detection and Follow-Up Program (HDFP): The Association of Standing Blood Pressures and Mortality in Hypertensives. *Circulation* 70(2):II-359, 1984.
55. Chervu LR, Sundoro BM, Blafox MD: Technetium-99m-labeled Para Amino-hippuric Acid Analog: A New Renal Agent. *J Nucl Med* 25(5):PI27, 1984.

56. Chervu LR, Sundoro BM, Blaurox MD: Technetium-99m Labeled Para Amino-hippuric Acid Analog: A New Renal Agent. Presented At Fifth International Symposium on Radiopharmaceutical Chemistry, Tokyo, July 1984.
57. Davis BR, Langford HL, Blaurox MD, Polk BF, Shulman NB, Curb JD: Postural Hypotension in a Hypertensive Population. Cardiovascular Disease Epidemiology Newsletter (of the AHA), No.37:47, January 1985.
58. Lee HB, Blaurox MD: Differential Effect of Captopril on GFR in Rats with Renovascular Hypertension. J Nucl Med 26(5):P72, 1985.
59. Langford HG, Ford CE, Blaurox MD, Shephard G (On Behalf of the Hypertension Detection and Follow-Up Program): Is Hypertension Worse in Blacks? Comparison of Creatinine Levels at Equal Blood Pressures. Cardiovascular Disease Epidemiology Newsletter (of the AHA), No. 37:32, 1985.
60. Kim CK, Fine EJ, Soberman R, Glicklick D, Blaurox MD: Changing Patterns of Renal Transplant (T) Rejection (R) with Cyclosporin Toxicity (Cyt). J Nucl Med 27:984, 1986.
61. Zuckier L.S, Finkelstein M., Stone P, Freed SZ, Bard R, Blaurox MD: Tc-99m Antimony Sulfide Colloid (SBSC) Lymphoscintigraphy of the Prostate by Direct Transrectal Injection. J Nucl Med. 27:1034, 1986.
62. Lee HB, Blaurox MD: Renal Functional Changes After Converting Enzyme (CE) Inhibition or Nitroprusside (NP) in Hypertensive Rats. J Nucl Med 27:1053, 1986.
63. Blaurox MD, Lee HB: Relation of Baseline Renal Function to Renographic Response to Captopril. J Nucl Med 28(4):612, 1987.
64. Davis B, Blaurox MD, Hawkins CM, Langford HG, Oberman A, Swencionis C, Wassertheil-Smoller S, Wylie-Rosett J, Zimbaldi: TAIM: Design, Methods, and Selected Baseline Results. Controlled Clin Trials 8:285-286, 1987.
65. Blaurox MD, Dubovsky EV, Britton KE, Hilson AJW: Categorical Seminar on Recent Advances and Current Status of Nuclear Medicine Studies of the Kidney. Proceedings of the International Symposium on Nuclear Medicine, Beijing, China, October 1988. In Proceedings of the Chinese Academy of Medical Sciences and the Peking Union Medical College, Vol. 3(3), Supplement I, 1988.
66. Lee HB, Blaurox MD: Tc-99m MAG3 Clearance After Captopril in Renovascular Hypertension (RVH). J Nucl Med 29(5):849, 1988.
67. Lee HB, Gale B, Blaurox MD: Differing Responses of 99m-Tc DMSA Uptake in Rats with Renovascular Hypertension (RVH) After Captopril. Am J Hyper 30(5):841, 1989.
68. Smoller SW, Blaurox MD, Davis B, Langford H, Oberman A, Knerr M, Swencionis C, for TAIM Group: The TAIM Study: Effects of Drug, Diet and Blood Pressure on Quality of Life. Am J Hyper 2(5), Part 2:16A, 1989.
69. Oberman B, Davis BR, Blaurox MD, Langford HG, Smoller S, Zimbaldi N, Blaszkowski TP, Rosett J. The Taim Study: Changes in Cardiovascular Risk Score with Treatment of Mild Hypertension. Am.J Hyper.2(5), Part 2:32A, 1989.
70. Lee HB, Gale B, Blaurox MD. Paradoxical Increased Glucoheptonate Uptake in Experimental Renovascular Hypertension. Am J Hyper 2(5), Part 2:42A, 1989.
71. Blaurox MD, Oberman A, Langford H, Davis B, Smoller S, Hawkins M, Zimbaldi N, Rosett J, for The TAIM Study Group: The TAIM Study: Effectiveness of Pharmacologic and Dietary Therapy of Hypertension. Am. J. Hyper. 2(5), Part 2:42A, 1989.

72. Lee HB, Blafox MD: Influence of Diuretic Therapy on Clearances Post Captopril (ACE) in Renovascular Hypertension (RVH). J Nucl Med 31(5):913, 1990
73. LeeHB,BlafoxMD:Effect Acute Diuresis Renal Function After Captopril (ACE). J Nucl Med31(5):913, 1990
74. Langford HG, Rockhold RW, Oberman A, Blafox MD, Smoller SW, Davis BR,(\* The University of Mississippi Medical Center, Jackson, MS): Diet, Antihypertensive Drugs and Erectile Difficulty in Man and Rats. Am J Hypertension 3(5) Part 2:24A, 1990.
75. Wassertheil-Smoller S., Blafox MD\*, Oberman A\*, Langford HG\*, Davis BR\*, Wylie-Rosett J (\* Albert Einstein College of Medicine): TAIM Study: Adequate Weight Loss As Effective As Drug Therapy for Mild Hypertension. Am J Hypertension 3(5) Part 2:101A, 1990.
76. Wassertheil-Smoller S., Langford H, Oberman A, Blafox MD\*, Zimbaldi N, Davis B (\* Albert Einstein College of Medicine): TAIM Study: Threshold Effect for Sodium Intake to Lower Blood Pressure. Am J Hypertension (3(5) Part 2:102A, 1990.
77. Langford HB, Davis B, Blafox MD, Oberman A, Wassertheil-Smoller S, Hawkins CM, Zimbaldi N: Effect of Drug and Diet Treatment of Mild Hypertension on Diastolic Blood Pressure. Ann Int Med 114:69, 1991.
78. Wassertheil-Smoller S, Blafox MD, Oberman A, Thaler L: Effect of Discontinuation of antihypertensive Drugs on Depressive Mood (DISH). Accepted for presentation International Society of Hypertension Meeting 1992.
79. Wassertheil-Smoller S, Derby C, Oberman A, Blafox MD, Hawkins CM, Langford HG: Effect or Discontinuation Antihypertensive Drugs Blood Lipids: he DISH Study. Am J Hyper 5(5) part 2:21A, 1992.
80. Blafox MD: Effect of Weight Reduction and Sodium Restriction/Potassium Supplementation on the Long-Term Control of Blood Pressure (Final Results of the TAIM Clinical Trial). Am J Hyper 5(5) part 2:21A, 1992.
81. Lee HB, Blafox MD:Captopril Mediated Hemodynamic Changes Renal Ischemia. J Nucl Med 33 (5):907, 1992.
82. Zuckier LS, Blafox MD, Ricciardi R, Melman A: Quantitative Dynamic Parameters to Evaluate Impotence. J Nucl Med 33:1723-1724, 1992.
83. Zuckier LS, Korupolu G, Gladshiteyn M. Sattenberg R, Ricciardi R, Goodwin P, Melman A, Blafox MD: Design and Implementation of a Circumferential Non-Imaging Probe with Superior Temporal Resolution for Measurement of Penile Hemodynamics. J Nucl Med 34 (5) 250p, 1993.
84. Lee HB, Blafox MD: Plasma Protein Binding of Renal Agents. J Nucl Med 34 (5): 250p, 1993.
85. Zhang CG, Fine EJ, Blafox MD: Captopril-Exercise Scintirenography. 34 (5):250p, 1993.
86. Lee HB, Blafox MD: Reduced Protein Binding of MAG3 in Renal Failure. J Nucl Med 35(5):265p, May 1994.
87. Blafox MD, Fine EJ, Chun J, Heller S, Blumenfeld J, Bongiovanni J: Exercise Renography in Untreated Patients with Mild to Moderate Hypertension. J Nucl Med 35(5):99p, May 1994.
88. Li Y, Lee HB, Blafox MD: Comparison of Single Sample Methods for Glomerular Filtration Rate (GFR). J Nucl Med 35(5):100p, May 1994.
89. Blafox MD, Middleton ML, Bongiovanni JA: The Efficacy of Screening Procedures for Renovascular Hypertension (RVH). J Nucl Med 35(5):265p, May 1994.
90. Li Y, Blafox MD: Effect of Captopril on Renal Mean Transit Time in Patients with Essential Hypertension. Nucl Med Communications 16(5):399-400, May 1995.

91. Zuckier LS, Kikut JK, Benet A, Melman A, Blafox MD: Quantitative Analysis of Tc-99m Red Blood Cell (RBC) Washin Time-Activity Curves (TAC's) for Determination of Cavernosal Blood Volume (BV) and Blood Flow (BF) in the Flaccid Penis. *J Nucl Med* 36(5):55p, May 1995.
92. Blafox MD, Fine EJ, Heller SH, Hurley J, Jagust M, Yi L, Mann S, Pickering T, Rackson M, Rottman GA, Sarkar S, Zanzonico P, Zhang CG: Simultaneous OIH and DTPA Captopril Renography (CR) in Hypertensives with Reduced Renal Function. *J Nucl Med* 36(5):44p, May 1995.
93. Moran JK, Lee HB, Blafox MD: Optimization of Urinary FDG Excretion during PET Imaging. *J Nucl Med* 39(5):250p, May 1998.
94. Blafox MD: Renin Profiling to Predict Response to Antihypertensive Therapy. *JAMA* 281(9):793, 1999.
95. Fine EJ, Blafox MD: Prediction Rule for Renal Artery Stenosis. *Ann Internal Medicine* 131(3):227, 1999.
96. Zhao DS, Valdivia A, Li Y, Blafox MD,: The Role of PET with <sup>18</sup>F-FDG in Small Cell Lung Cancer. *J Nucl Med* 42(5):75p, May 2001.
97. Zhang T, Jana S, Milstein DM, Blafox MD: FDG-PET and CT Characterization of Adrenal Lesions of Cancer Patients. *J Nucl Med* 44(5)124P, May 2003.
98. Stanger R, Jana S, Milstein DM, Moadel R, Isasi C, Blafox MD: Accuracy of CT Transmission Maps in PET Imaging Studies. *J Nucl Med* 45(5):41p, May 2004.
99. Zhang T, Jana S, Milstein DM, Blafox MD: Measurement of Maximum Diameter of Metabolically Active Tumor as an Alternative to SUV for Monitoring Tumor Response in PET. *J Nucl Med* 45(5):101p, May 2004.
100. Moadel RM, Dadachova E, Blafox MD: Dosimetry of <sup>18</sup>F-2-Deoxy-2-Fluoro-D-Glucose (FDG) as a Therapeutic Agent in Malignancy. *J Nucl Med* 45(5):55p, May 2004.
101. Moadel RM, Dohan O, Vuolo M, Negassa A, Isasi CR, Sparano JA, Blafox MD, Carrasco N: In Vivo Detection of Na<sup>+</sup>/I<sup>-</sup> Symporter (NIS) Activity by <sup>99m</sup>Tc-Perchnetate (TcO<sub>4</sub>) Scintigraphy in Human Breast Cancer Metastases Suggests <sup>131</sup>I as a Novel Therapeutic Agent. *J Nucl Med* 45(5):194p May 2004.
102. Isasi CR, Moadel R, Blafox MD: Meta-Analysis of FDG-PET Use in Breast Cancer Recurrence and Metastases. *J Nucl Med* 45(5):353p May 2004.
103. Khandani AH, Whitney KD, Keller SM, Isasi C, Madan R, Blafox MD: 18-F FDG PET and Proliferative Index of Stroma in Bronchioloalveolar Lung Cancer. *J Nucl Med* 45(5):378p May 2004.
104. Jana S, Soto D, Aghalar J, Spektor M, Milstein DM, Moadel R, Isasi CR, Blafox MD: Effects of <sup>137</sup>Cs and CT Attenuation Correction on FDG-PET Images. *J Nucl Med* 46(2):476p May 2005.
105. Aghalar J, Jana S, Heller S, Isasi CR, Blafox MD: ECT of Respiratory Motion on SUV Variation of a Lung Lesion when Comparing <sup>137</sup>Cs and CT Attenuation Corrected FDG-PET Images. *J Nucl Med* 46(2):475p, May 2005.
106. Chan S, Isasi CR, Negassa A, Dadachova E, Blafox MD: Safety and Feasibility of Positherapy with <sup>18</sup>FDG in Metastatic Malignancy. *J Nucl Med* 46(2):340p, May 2005.
107. Lu P, Milstein DM, Valdivia A, Travin M, Moadel R, Jana S, Blafox MD; Diagnostic Value of Rubidium-82 Myocardial Perfusion PET in Women with Equivocal TC-99M-Sestamibi Gated Myocardial Perfusion SPECT. *J Nucl Med* 46(2)115p, May 2005.
108. Jana S, Mahadeo S, Heller S, Isasi CR, Blafox MD: Influence of PET Scanners, Lesion Size, and Attenuation Correction Methods on SUV in FDG-PET Imaging. *J Nucl Med* 46(2)114p, May 2005.

109. Jana S, Aghalar J, Soto D, Milstein D, Moadel R, Isasi C, Blafox M: Effects of  $^{137}\text{Cs}$  and CT attenuation correction on FDG-PET images: A prospective semiquantitative evaluation. *J Nucl Med* 47(1)384p, June 2006.
110. Koba W, Jana S, Paul P, Heller S, Blafox M: A simplified one-day technique for measuring dose calibrator linearity with  $^{18}\text{F}$  and  $^{99\text{m}}\text{Tc}$ . *J Nucl Med* 47(1)407p, June 2006.
111. Miao W, Fine EJ, Koba W, Blafox MD: Cardiac  $^{18}\text{F}$ -FDG uptake in Wistar rats varies with dietary carbohydrate (CHO) content. *J Nucl Med* 49(1)32p, May 2008.
112. Das BC, Mani S, Blafox MD: Design and Synthesis 3-Phenyl-2H-Benzo[b][1,4]Oxazine Containing PET Imaging Agent for Hypoxia. *J Nucl Med* 50(4)660p, April 2009.
113. Chamarthy M, Shapoval A, Blafox M, Freeman L: Marrow visualization on renal scintigraphy: An often overlooked finding in azotemic patients. *J Nucl Med* 51(2)1680p, June 2010

05/23/16 CV MDB